Document:

EX-10.6

 Exhibit 10.6 

USE AND OCCUPANCY AGREEMENT 

This Use and Occupancy Agreement (“Agreement”) is effective as of the 1st day of July, 2021, by Atlas Venture Life Science Advisors,
LLC, a Delaware limited liability company (“Tenant”) and Third Harmonic Bio, Inc., with an address of 300 Technology Sq., Cambridge, MA 02139 (“Occupant”). 

WHEREAS, Tenant, as tenant, and Are-Tech Square, LLC, a Delaware limited liability company (
“Landlord”) entered into that certain Lease Agreement dated June 19, 2019 (the “Lease”), of certain premises comprised of 17,476 rentable square feet of space (the “Premises”), in the building known as 300
Technology Square, Cambridge, Massachusetts (the “Building”); This Agreement and the rights and responsibilities of the parties hereunder are subject and subordinate to the terms and provisions of the Lease. 

WHEREAS, Tenant has agreed to grant Occupant a license for non-exclusive use and occupancy rights with
respect to certain space comprised of an area of the Premises designated by Tenant as more particularly described in Exhibit B (collectively, the “Occupancy Area”), together with certain rights appurtenant thereto, as may be amended
from time to time upon agreement of the parties; and 
 WHEREAS, Occupant has agreed to use and occupy the Occupancy Area in accordance with
this Agreement. 
 NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby mutually
acknowledged, Tenant and Occupant, each with intent to be legally bound, agree to the following: 
 1. USE AND OCCUPANCY 

Tenant agrees that, commencing as of July 1, 2021 (the “Occupancy Commencement Date”), and continuing for the remainder of the
term of this Agreement, Occupant may use and occupy the Occupancy Area on the terms and conditions contained in this Agreement, in its present “AS IS” condition on the date hereof. 

2. TERM 
 The term
of this Agreement shall commence on the Occupancy Commencement Date and, subject to the provisions set forth herein, shall continue for an initial nine month period, and continuing thereafter on a month to month basis unless terminated by either
party upon 60 days’ prior written notice given by either party to the other (said date, the “Termination Date”). In no event will the term of this Agreement extend beyond the expiration or earlier termination of the Lease. 

  
 1 

 3. USE FEE AND
SHARED SERVICES FEE 
 The Use Fee Schedule attached hereto as Exhibit C
and incorporated herein, outlines the occupancy charges (the “Use Fee”) for the Occupancy Area and common areas and charges for shared services (the “Shared Services Fee”) as of the Effective Date. In the event that the
Occupancy Area is amended during the term, the Use Fee shall be adjusted to reflect the revised Occupancy Area. The Shared Services Fee may be amended from time to time by the Tenant upon notice to the Occupant. Occupant shall pay from the Occupancy
Commencement Date until the Termination Date the Use Fee and the Shared Services Fee, as provided in Exhibit C, to Tenant, payable in advance on or before the first day of each calendar month during the term of this Agreement. If the term of
this Agreement should expire other than on the last day of a month, any full month installment of Use Fee and the Shared Services Fee paid by Occupant and allocable to such partial month shall be equitably apportioned. 

4. USE OF THE OCCUPANCY
AREA 
 (a) Occupant may use and occupy the Occupancy Area as contemplated hereby solely for general office purposes.
Occupant shall install and provide its own independent computer equipment. The “common area” corridors, stairs, and entryways providing direct access to the Occupancy Area, as well as restrooms and common lobbies on the floor of the
Building on which the Occupancy Area is located, and the lounge, dining areas, reception areas, conference room and other areas within the Premises designated by Tenant from time to time for the common use of all occupants of the Premises, shall
constitute the “Common Areas.” Occupant shall be entitled to reasonable use and occupancy of the Common Areas in order to have access to the Occupancy Area, and to use the bathrooms on the floor of the Building on which the Occupancy Area
is located and to conduct its business within the Premises. 
 (b) Occupant shall be responsible for any violations of all Federal, state
and local laws, ordinances, rules and regulations and the requirements of any Board of Fire Insurance Underwriters arising by virtue of Occupant’s manner of use of the Occupancy Area. 

(c) Occupant shall keep the Occupancy Area in good order and condition subject to reasonable wear and tear and, at the Termination Date, shall
remove all of Occupant’s personal property and surrender the Occupancy Area in the condition required hereunder. Any damage caused to the Occupancy Area by such removal shall be repaired by Occupant in a good and workmanlike manner, at
Occupant’s sole cost and expense. 
 (d) Occupant shall be responsible for any repair or maintenance of the Occupancy Area which is the
consequence of Occupant’s act or omission. If Tenant shall perform alterations to any portion of the Premises, Tenant shall exercise reasonable efforts to minimize any interference with Occupant’s use of the Occupancy Area. 

(e) Occupant acknowledges and agrees that its occupancy of certain Occupancy Areas may be on an exclusive or
non-exclusive basis (with such exclusive areas designated on Exhibit B), all use of the common areas are on a non-exclusive basis, and that Tenant may grant
additional rights to use the Premises to such other parties as Tenant may desire, in its sole discretion, provided that such additional occupancy rights do not materially adversely affect Occupant’s use of the Occupancy Area. 

  
 2 

 5. EXTRA SERVICES 

(a) Tenant shall provide to Occupant, at no additional cost to Occupant, the following services: (i) High-speed internet; (ii) VoIP
telephony; (iii) wireless network connectivity; (iv) access to Common Area conference rooms, on space available basis; (v) access to pantry/lunchroom in the Premises; (vi) staffed reception desk in the main suite; and
(vii) copy and printing, fax and scan capabilities. 
 (b) Any other services required by the Occupant are at its sole cost and expense
unless separately agreed to in writing by Occupant and Tenant. 
 6. ALTERATIONS 

Occupant shall not make any alterations, improvements or installations in or to the Occupancy Area without the prior written consent of
Tenant, which consent may be withheld in Tenant’s sole and absolute discretion. 
 7. ASSIGNMENT
AND SUBLETTING 
 Occupant shall not assign this Agreement or sublet the Occupancy Area.

 8. INSURANCE 

Occupant, at its sole cost and expense, shall, throughout the term of this Agreement, procure, keep in force and pay for a policy of general
liability and property damage insurance as required under the terms of the Lease, the insurance provisions of which are attached as Exhibit A. Occupant shall indemnify Landlord and Tenant and hold them harmless against all
claims and demands for bodily injury to or death of persons or damage to property which may be claimed to have arisen out of the use of the Occupancy Area and any common areas by Occupant or its partners, employees, agents, independent contractors
or invitees. Occupant’s liability insurance policies shall have such other characteristics as are required under the Lease and Occupant shall provide evidence of such insurance reasonably satisfactory to Tenant and Landlord on or before the
Commencement Date. 
 The property insurance obtained by Occupant shall include a waiver of subrogation by the insurers and all rights based
upon an assignment from its insured, against Landlord or Tenant, and their respective officers, directors, employees, managers, agents, invitees and contractors (“Related Parties”), in connection with any loss or damage thereby insured
against. Neither party nor its respective Related Parties shall be liable to the other for loss or damage caused by any risk insured against under property insurance carried by either party (so long as each party carries such insurance as is
required to be maintained hereunder), and each party waives any claims against the other party, and its respective Related Parties, for such loss or damage. The failure of a party to insure its property shall not void this waiver. Landlord, Tenant
and their respective Related Parties shall not be liable for, and Occupant hereby waives all claims against such parties for, business interruption and losses occasioned thereby sustained by Occupant or any person claiming through Occupant resulting
from any accident or occurrence in or upon the Premises or relating to the incubator company’s preliminary operations, design, innovation and other related early stage development (the “Project”) from any cause whatsoever. If the
foregoing waivers shall contravene any law with respect to exculpatory agreements, the liability of Landlord or Tenant or Occupant shall be deemed not released but shall be secondary to the other’s insurer. 

  
 3 

 9. INDEMNITY 

Occupant agrees to indemnify and save harmless Tenant and Landlord and each of their respective partners, employees, agents, independent
contractors, clients and invitees each an “Indemnified Party” and collectively, the “Indemnified Parties”), from and against any and all claims, liabilities, suits, judgments, awards, damages, losses, fines, penalties, costs and
expenses, including without limitation reasonable attorneys’ fees, that any Indemnified Party may suffer, incur or be liable for by reason of or arising out of the breach by Occupant or Occupant’s employees, agents, independent contractors
or invitees of any of the duties, obligations, liabilities or covenants applicable hereunder or relating to its occupancy or use of the Premises. Occupant shall promptly notify Tenant of any such claim and shall promptly deliver to the other a copy
of any summons or other process, pleading or notice issued in any action or proceeding to assert any such claim. Occupant shall, upon the written request of any Indemnified Party, defend any such action or proceeding at its own cost and expense.

 10. OCCUPANT’S OBLIGATIONS
UPON TERMINATION OF THIS AGREEMENT 

Occupant agrees that it will keep the Occupancy Area in substantially the same condition as received on the Commencement Date, and will, at
the Termination Date or other termination of the term of this Agreement, surrender and deliver up the same in like condition, ordinary wear and tear and damage by the elements, condemnation, fire, and other casualty excepted. Failure to so timely
surrender the Occupancy Area, time being of the essence, shall render Occupant an occupant at sufferance. 
 11. BROKERS 

The Occupant represents to Tenant that no broker was used in connection with the execution of this Agreement and agrees to indemnify and hold
the Tenant harmless from any and all claims of any other broker claiming to have dealt with the Occupant. Tenant represents to the Occupant that no broker was used in connection with the execution of this Agreement and agrees to indemnify and hold
the Occupant harmless from any and all claims of any other broker claiming to have dealt with the Tenant. 
 12. DEFAULTS 

Each of the following shall be a default of Occupant: 

(a) Occupant fails to make any payment of Use Fee or Shared Services Fee when such payment is due and such failure shall continue for five
(5) days after written notice from Tenant to Occupant (“Monetary Default”). 
 (b) Except as provided in clause
(c) below, Occupant fails to perform any obligation of Occupant pursuant to this Agreement other than a Monetary Default, and that failure continues for fifteen (15) days after written notice from Tenant. 

  
 4 

 (c) Occupant fails to timely surrender the Occupancy Area pursuant to Paragraph 10 hereof,
in which case the terms and conditions of said Paragraph 10 shall apply, and Tenant shall additionally have the remedies described in Paragraph 13 below. 

13. REMEDIES 
 (a)
In the event of a default by Occupant, Tenant shall have the power and right: 
 (i) To enforce any remedies generally available at law or
in equity to a landlord upon a default by tenant; 
 (ii) To obtain injunctive relief against any continuing default by Occupant; 

(iii) To maintain this Agreement in effect and collect the Use Fee and Shared Services Fee due from Occupant to Tenant; 

(iv) To exercise Tenant’s rights under Paragraph 10 in the case of any holding over by Occupant; and 

(v) To terminate this Agreement and recover exclusive possession of the Occupancy Area. Occupant nevertheless agrees to remain liable for any
and all damage, deficiency or loss of Use Fee and Shared Services Fee which Tenant may sustain by reason of the exercise of such remedies. 

(b) In the event of a compromise or settlement of any default, such compromise or settlement shall not constitute a waiver of any breach or
any covenant, condition or agreement herein contained, nor shall it operate as a waiver of the covenant, condition or agreement itself, or of any subsequent breach thereof. 

14. FIRE, CASUALTY AND EMINENT
DOMAIN 
 In the event of a fire, casualty or taking that affects the Premises but that does not result in termination of the Lease,
the Use Fee and Shared Services Fee hereunder shall be abated in the direct proportion which the rent payable by Tenant under the Lease and allocable to the Occupancy Area is abated. The provisions of this Paragraph 14 shall be considered an express
agreement governing any cause of damage or destruction to the Occupancy Area by fire or other casualty, and no local or state statute, law, rule or regulation, now or hereafter in effect, providing for such a contingency shall have any application
in such case, to the extent permitted by law. 
 15. SEVERABILITY AND
GOVERNING LAW 
 This Agreement shall be construed and interpreted in accordance with the
laws of the Commonwealth of Massachusetts. If any provision hereof or the application hereof to any person or circumstance shall to any extent be invalid or unenforceable, the remaining provisions hereof, or the application of such provision to the
person or circumstances other than those as to which it is invalid or unenforceable, shall not be affected thereby, and each provision hereof shall be valid and enforceable to the extent permitted by law. 

  
 5 

 16. NOTICES 

Any notice, statement, certificate, consent, approval, disapproval, request or demand required or permitted to be given in this Agreement
shall be in writing delivered (a) by hand, (b) by reputable overnight courier, or (c) by email with receipt acknowledged: 

To Tenant at the following address: 

Atlas Venture Life Science Advisors, LLC 

300 Technology Square 
 Cambridge,
MA 02139 
 Email: 
 and to
Occupant at the Occupancy Area: 
 Attn: Howard Davis 

Third Harmonic Bio, Inc. 
 300
Technology Square 
 Cambridge, MA 02139 

Email: 
 Either party by notice
to the other may change or add persons and places where notices are to be sent or delivered. In no event shall notice have to be sent on behalf of either party to more than two (2) persons. Notices will be deemed served when received by hand,
delivery by reputable overnight courier providing receipt of delivery, or in the case of email, upon acknowledged receipt. 
 17.
SERVICES, NO REAL ESTATE INTEREST; SIGNAGE. 

Except as otherwise expressly set forth in this Agreement, Tenant shall not be obligated to deliver any services to Occupant in connection
with its use of the Occupancy Area. This Agreement grants non-exclusive rights of use and occupancy only. No interest in real estate is granted. Occupant will not be entitled to signage in the lobby of the
Building or elsewhere on the Premises. 
 18. ENTIRE AGREEMENT 

This Agreement contains the entire agreement between Tenant and Occupant and can be changed only by an amendment executed by both Tenant and
Occupant. 
 19. NOTICE OF AGREEMENT 

Tenant and Occupant agree that neither party shall record this Agreement, nor shall Occupant have any right to record a notice of this
Agreement. 

  
 6 

 20. BINDING EFFECT 

The submission of this Agreement for examination and negotiation does not constitute an offer to sublease or a reservation of, or an option
for, the Occupancy Area. Once fully executed, all the covenants, agreements and undertakings in this Agreement contained shall extend to and be binding upon the legal representatives, successors and assigns of the respective parties hereto, the same
as if they were in every case named and expressed, but nothing herein shall be construed as a consent by Tenant to any assignment or subletting by Occupant of any interest of Occupant in this Agreement. 

21. COUNTERPARTS 

This Agreement may be executed in one or more counterparts, each of which shall constitute an original and all of which shall constitute but
one agreement. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature process complying with the U.S. federal ESIGN Act of 2000) or other transmission method and any counterpart so delivered shall be
deemed to have been duly and validly delivered and be valid and effective for all purposes. Electronic signatures shall be deemed original signatures for purposes of this Agreement and all matters related thereto, with such electronic signatures
having the same legal effect as original signatures. 

  
 7 

 IN WITNESS WHEREOF, Tenant and Occupant have each caused these presents to be executed as a
sealed instrument as of the day and year first above written. 
  

			
	TENANT:
	
	ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC,
	a Delaware limited liability company
		
	By:	 	 /s/ Ommer Chohan

		 	Name: Ommer Chohan
		 	Title: CFO
	
	OCCUPANT:
	
	THIRD HARMONIC BIO, INC.
		
	By:	 	 /s/ Howard Davis

		 	Name: Howard Davis
		 	Title: COO

  
 8 

 EXHIBIT A 

Insurance Requirements 
 PLEASE NOTE FOR
THE PURPOSE OF THIS EXHIBIT A THAT ALL REFERENCES TO “TENANT” SHALL APPLY AND REFER TO THE OCCUPANT AND ALL REFERENCES TO “LANDLORD” SHALL APPLY AND REFER TO THE LANDLORD AND TENANT. 

Landlord shall maintain all risk property and, if applicable, sprinkler damage insurance covering the full replacement cost of the Project,
including Landlord’s Work. Landlord shall further procure and maintain commercial general liability insurance with a single loss limit of not less than $2,000,000 per occurrence for bodily injury and property damage with respect to the Project.
Landlord may, but is not obligated to, maintain such other insurance and additional coverages as it may deem necessary, including, but not limited to, flood, environmental hazard and earthquake, loss or failure of building equipment, errors and
omissions, rental loss during the period of repair or rebuilding, workers’ compensation insurance and fidelity bonds for employees employed to perform services and insurance for any improvements installed by Tenant or which are in addition to
the standard improvements customarily furnished by Landlord without regard to whether or not such are made a part of the Project. All such insurance shall be included as part of the Operating Expenses. The Project may be included in a blanket policy
(in which case the cost of such insurance allocable to the Project will be determined by Landlord based upon the insurer’s cost calculations). 

Tenant, at its sole cost and expense, shall maintain during the Term: all risk property insurance covering the full replacement cost of all
property and improvements installed or placed in the Premises by Tenant at Tenant’s expense (not including Landlord’s Work); workers’ compensation insurance with no less than the minimum limits required by law; employer’s
liability insurance with such limits as required by law; and commercial general liability insurance, with a minimum limit of not less than $2,000,000 per occurrence for bodily injury and property damage with respect to the Premises. The commercial
general liability insurance policy shall name Landlord, its officers, directors, employees, managers and agents and the Additional Insured Parties (as defined in the next succeeding paragraph) (collectively, “Landlord Parties”), as
additional insureds; insure on an occurrence and not a claims-made basis; be issued by insurance companies which have a rating of not less than policyholder rating of A and financial category rating of at least Class X in “Best’s
Insurance Guide”; shall not be cancelable for nonpayment of premium unless 30 days prior written notice shall have been given to Landlord from the insurer; contain a hostile fire endorsement and a contractual liability endorsement; and provide
primary coverage to Landlord (any policy issued to Landlord providing duplicate or similar coverage shall be deemed excess over Tenant’s policies). Certificates of insurance showing the limits of coverage required hereunder and showing Landlord
as an additional insured, along with reasonable evidence of the payment of premiums for the applicable period, shall be delivered to Landlord by Tenant upon commencement of the Term and upon each renewal of said insurance. Tenant’s policy may
be a “blanket policy” with an aggregate per location endorsement which specifically provides that the amount of insurance shall not be prejudiced by other losses covered by the policy. Tenant shall, at least 5 days prior to the expiration
of such policies, furnish Landlord with renewal certificates. 

 In each instance where insurance is to name Landlord as an additional insured, Tenant shall
upon written request of Landlord also designate and furnish certificates so evidencing Landlord as additional insured to the following parties (collectively “Additional Insured Parties”): (i) any lender of Landlord holding a
security interest in the Project or any portion thereof and any servicer in connection therewith, (ii) the landlord under any lease wherein Landlord is tenant of the real property on which the Project is located, if the interest of Landlord is
or shall become that of a tenant under a ground or other underlying lease rather than that of a fee owner, (iii) any management company retained by Landlord to manage the Project, (iv) the condominium association with respect to the
Condominium, (v) any member, partner or shareholder of Landlord or the owner of any beneficial interest therein and/or (vi) any other party reasonably designated by Landlord. 

The property insurance obtained by Landlord and Tenant shall include a waiver of subrogation by the insurers and all rights based upon an
assignment from its insured, against Landlord or Tenant, and their respective Related Parties, in connection with any loss or damage thereby insured against. Neither party nor its respective Related Parties shall be liable to the other for loss or
damage caused by any risk insured against under property insurance required to be maintained hereunder, and each party waives any claims against the other party, and its respective Related Parties, for such loss or damage. The failure of a party to
insure its property shall not void this waiver. Landlord and its respective Related Parties shall not be liable for, 
 and Tenant hereby
waives all claims against such parties for, business interruption and losses occasioned thereby sustained by Tenant or any person claiming through Tenant resulting from any accident or occurrence in or upon the Premises or the Project from any cause
whatsoever. If the foregoing waivers shall contravene any law with respect to exculpatory agreements, the liability of Landlord or Tenant shall be deemed not released but shall be secondary to the other’s insurer. 

Landlord may require insurance policy limits to be raised to conform with requirements of Landlord’s lender and/or to bring coverage
limits to levels then being generally required of new office tenants within the Project; provided, however, that the increased amount of coverage is consistent with coverage amounts then being required by institutional owners of similar projects
with office tenants occupying similar size premises in the geographical area in which the Project is located. 

 EXHIBIT B 

Occupancy Area 

 EXHIBIT C 

Use Fee and Shared Services Fee 
 Use Fee:

 Office 880 (4 desks / 256 rsf): $5,722 per month. 
 Note:
Projected increase to ~ $6,442 in Q3 2021 and beyond based on level of amenities offered at the time, subject to state and building Covid-19 guidelines.EX-10.7

 Exhibit 10.7 

EXECUTION COPY 

CONFIDENTIAL 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, 

MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS 

THE TYPE THAT THIRD HARMONIC BIO, INC. TREATS AS PRIVATE OR 

CONFIDENTIAL. 

LICENSE AGREEMENT 

This License Agreement (“Agreement”) is entered into as of June 28, 2019 (the “Effective Date”)
by and between Novartis International Pharmaceutical Ltd., a for profit corporation with its principal place of business at Lichtstrasse 35, CH-4056 Basel, Switzerland (“Novartis”) and Third
Harmonic Bio, Inc. (hereinafter referred to as “NewCo”). Novartis and NewCo are each referred to individually as a “Party” and together as the “Parties.” 

Background 
 Novartis
Controls (as defined below) the Licensed Patents and the Licensed Know-How (each as defined below) relating to the Licensed Compounds (as defined below). NewCo is in the business of discovering, developing and
commercializing pharmaceutical products, and NewCo wishes to obtain, and Novartis wishes to grant, rights under the Licensed IP (as defined below) to develop, make, use and sell Licensed Products (as defined below) incorporating the Licensed
Compounds. 
 Therefore, the Parties agree as follows: 

1. DEFINITIONS AND INTERPRETATION 
 1.1
Definitions. Unless the context otherwise requires, the terms in this Agreement with initial letters capitalized will have the meanings set forth below, or the meaning as designated in the indicated places throughout this Agreement. 

“Accounting Standards” means, with respect to NewCo, US GAAP (Generally Accepted Accounting Principles) and means, with
respect to Novartis, IFRS (International Financial Reporting Standards), in each case as generally and consistently applied throughout the Party’s organization. Each Party will promptly notify the other Party if such Party changes the
Accounting Standards pursuant to which its records relating to this Agreement are maintained; provided, however, that each Party may only use internationally recognized accounting principles (e.g., IFRS or US GAAP). 

“Additional Equity Notice” has the meaning set forth in Section 8.3(c). 

“Affiliate” means, with respect to a Party, any Person that controls, is controlled by, or is under common control with that
Party. For the purpose of this definition, “control” will mean, direct or indirect ownership of 50% or more of the shares of stock entitled to vote for the election of directors, in the case of a corporation, or 50% or more of the equity
interest in the case of any other type of legal entity, status as a general partner in any partnership, or any other arrangement 

 
whereby the entity or Person controls or has the right to control the board of directors or equivalent governing body of a corporation or other entity, or the ability to cause the direction of
the management or policies of a corporation or other entity. In the case of entities organized under the laws of certain countries, the maximum percentage ownership permitted by law for a foreign investor may be less than 50%, and in such case such
lower percentage will be substituted in the preceding sentence, provided that such foreign investor has the power to direct the management and policies of such entity. 

“Agreement Term” has the meaning set forth in Section 11.1(a). “Alliance Manager” has the meaning set
forth in Section 3.1. “ANDA” has the meaning set forth in Section 9.5(a). 
 “Applicable Law”
means any federal, state, local or foreign law (including, common law), statute or ordinance, or any rule, regulation, judgment, order, writ or decree of or from any court, or other Regulatory Authority having jurisdiction over or related to the
subject item that may be in effect from time to time, including, as applicable, GCP, GLP, and GMP. 
 “Auditor” has the
meaning set forth in Section 8.8(b). 
 “Calendar Quarter” means the respective periods of three (3) consecutive
calendar months ending on March 31, June 30, September 30, and December 31; provided, that the first Calendar Quarter of this Agreement shall commence on the Effective Date and end on June 30, 2019, and the last Calendar
Quarter of this Agreement shall end on the date of expiration or termination of this Agreement in its entirety. 
 “Calendar
Year” means a period of twelve (12) consecutive calendar months ending on December 31; provided, that the first Calendar Year of this Agreement shall commence on the Effective Date and end on December 31, 2019, and the last
Calendar Year of this Agreement shall end on the date of expiration or termination of this Agreement in its entirety. 

“Claims” means all Third Party demands, claims, actions, proceedings and liability (whether criminal or civil, in contract,
tort or otherwise) for losses, damages, reasonable legal costs, and other reasonable expenses of any nature whatsoever. 

“Code” has the meaning set forth in Section 2.5. 

“Commercialization Milestone” has the meaning set forth in Section 8.4(a). “Commercialization Milestone
Payment” has the meaning set forth in Section 8.4(a). 
 “Commercialize” means to manufacture, market,
promote, distribute, import, export, offer to sell or sell Licensed Compounds or Licensed Products, as well as conducting all associated post-launch regulatory activities, including medical affairs oversight and post-approval studies, and any
activities directed to obtaining pricing or reimbursement approvals, and “Commercialization” means commercialization activities relating to Licensed Products. 

“Commercially Reasonable Efforts” means, with respect to a Party, the efforts and resources typically used by reasonable,
similarly situated biotechnology or pharmaceutical companies to perform the obligation at issue, which efforts will not be less than those efforts made by such Party with respect to other products at a similar stage of development or in a similar
stage 

 
of product life, with similar developmental risk profiles, of similar market and commercial potential, taking into account the efficacy, safety, expected or approved labeling, and market
exclusivity and other proprietary position of such product as well as the competitiveness thereof, the likelihood of Regulatory Approval thereof given the regulatory structure involved and any jurisdictional-specific regulatory or clinical
development requirements, the profitability to such Party, and the costs, liabilities and external and internal resources required to achieve the relevant objective, but without regard for any payments owed under this Agreement. For the avoidance of
doubt, where a Party has an obligation to use Commercially Reasonable Efforts, the efforts of such Party and its Affiliates and Sublicensees shall be considered in determining whether such Party has satisfied such obligation. 

“Confidential Information” means all Know-How and other confidential or proprietary
information and data of a financial, commercial or technical nature, including information comprising or relating to concepts, discoveries, inventions, data, designs or formulae, which the disclosing Party, its Affiliates, or its or their licensors
has supplied or otherwise made available to the other Party or its Affiliates, prior to or during the Agreement Term, whether made available orally, in writing or in electronic form, pursuant to this Agreement. 

“Control” or “Controlled” means, with respect to any Know-How,
Patent Rights, other intellectual property rights, or any proprietary or trade secret information, the legal authority or right (whether by ownership, license or otherwise, other than by a license granted under this Agreement) of a Party or its
Affiliates, to grant a license or a sublicense of or under such Know- How, Patent Rights, or intellectual property rights to another Person, or to otherwise disclose such proprietary or trade secret information to another Person, without breaching
the terms of any agreement with a Third Party or misappropriating the proprietary or trade secret information of a Third Party. 

“Cover”, “Covered” or “Covering” means, with respect to a Valid Claim of a Patent Right and
a product or other subject matter, that, in the absence of ownership of, or a license under such Patent Right (i) with respect to a Valid Claim that is issued or granted, the manufacture, use, offer for sale, sale or importation of such product
or other subject matter would infringe such Valid Claim of such Patent Right, or (ii) in the case of a Valid Claim that is pending, the manufacture, use, offer for sale, sale or importation of such product or other subject matter would infringe
such Valid Claim if such Valid Claim were actually issued. 
 “CTA” has the meaning set forth in Section 5.1. 

“Develop” or “Development” means drug development activities, including, manufacture of the Licensed
Compounds or Licensed Products, test method development and stability testing, assay development and audit development, toxicology, formulation, quality assurance/quality control development, statistical analysis,
pre-clinical studies, clinical studies, packaging development, regulatory affairs, and the preparation, filing, and prosecution of Regulatory Filings as necessary to obtain Regulatory Approval to market or
sell a Licensed Product. 
 “Development Milestone” has the meaning set forth in Section 8.3(a). 

“Development Milestone Payment” has the meaning set forth in Section 8.3(a). 

 “Development Plan” has the meaning set forth in Section 3.2(a). 

“Dispute” has the meaning set forth in Section 15.5(a). 

“Effective Date” has the meaning in the preamble (i.e., in the first paragraph of this Agreement). 

“Encumbrance” means any claim, charge, equitable interest, hypothecation, lien, mortgage, pledge, option, license,
assignment, power of sale, retention of title, right of pre-emption, right of first refusal or security interest of any kind. 

“Existing CDA” means the Confidentiality Agreement entered into by and between Novartis Institutes for BioMedical Research,
Inc. (an Affiliate of Novartis) and Atlas Venture having an office at [*], effective as of March 12, 2019. 
 “Expedited
Resolution” shall have the meaning set forth in Section 15.6. 
 “FDA” means the United States Food and Drug
Administration or any successor entity thereto. 
 “Field” means [*] 

“Financing Transaction” has the meaning set forth in Section 8.2. 

“First Commercial Sale” means the first sale of a Licensed Product by NewCo, its Affiliates or a Sublicensee (for the purpose
of this definition, “Sublicensees” will not include any distributors or wholesalers) to a Third Party (including a governmental authority) in a country after receipt of Regulatory Approval and Pricing and Reimbursement Approval (to the
extent applicable for Commercialization) of such Licensed Product in such country. 
 “Force Majeure” has the meaning set
forth in Section 15.7. 
 “GCP” means the ethical, scientific, and quality standards required by the FDA or the
European Commission for designing, conducting, recording, and reporting trials that involve the participation of human subjects, as set forth in FDA regulations in 21 C.F.R. Parts 11, 50, 54, 56, and 312 and related FDA guidance documents, and by
the International Conference on Harmonization E6: Good Clinical Practices Consolidated Guideline, or as otherwise required by Applicable Laws. 

“Generic Equivalent” means, with respect to a particular Licensed Product in a country, any other product that: 

(a) has Regulatory Approval for use in such country pursuant to a regulatory process governing approval of generic products
where such Regulatory Approval relied on or incorporated clinical data generated by or on behalf of either Party to this Agreement or their respective Affiliates, licensees or Sublicensees, and was obtained by a Person other than NewCo or its
Affiliates or a licensee or Sublicensee thereof using an abbreviated, expedited, or other similar process; and 

 (b) is not owned or licensed by NewCo or its Affiliates or a licensee or
Sublicensee thereof during the Royalty Term. 
 “Global Safety Database” has the meaning set forth in Section 5.3.

 “GLP” means good laboratory practice as required by the FDA under 21 C.F.R. part 58 and all applicable FDA rules,
regulations, orders and guidances, and the requirements with respect to current good laboratory practices prescribed by the European Community, the OECD 

(Organization for Economic Cooperation and Development Council) and the ICH Guidelines, or as otherwise required by Applicable Laws. 

“GLP Toxicology Study” means a toxicology study, in a species that satisfies applicable regulatory requirements, using
applicable GLP that meets the standard necessary for submission as part of an IND Filing with the applicable Regulatory Authority. 

“GMP” means good manufacturing practices and regulations as required by the FDA under provisions of 21 C.F.R. parts 210 and
211 and all applicable FDA rules, regulations, orders and guidances, and the requirements with respect to current good manufacturing practices prescribed by the European Community under provisions of “The Rules Governing Medicinal Products in
the European Community, Volume 4, Good Manufacturing Practices, Annex 13, Manufacture of Investigational Medicinal Products, July 2003,” or as otherwise required by Applicable Laws. 

“ICC” has the meaning set forth in Section 15.5(b). 

“IND” means an application submitted to a Regulatory Authority to initiate human clinical trials, including (a) for the
United States, an Investigational New Drug application or any successor application or procedure filed with the FDA pursuant to 21 C.F.R. part 312, (b) any equivalent to the application or procedure referenced in clause (a) in any country
outside the United States, and (c) all supplements and amendments that may be filed with respect to (a) or (b). 
 “IND
Filing” means the filing with a Regulatory Authority in a Major Market Country of an IND. 
 “Indemnification Claim
Notice” has the meaning set forth in Section 14.3(b). 
 “Indemnified Party” has the meaning set forth in
Section 14.3(b). 
 “Indemnifying Party” has the meaning set forth in Section 14.3(b). 

“Indication” means [*]. 

“Infringement Claim” has the meaning set forth in Section 9.8. 

“Insolvency Event” means, with respect to a Party, 

(a) such Party ceases to function as a going concern by suspending or discontinuing its business; 

 (b) such Party is the subject of voluntary or involuntary bankruptcy
proceedings instituted on behalf of or against such Party (except for involuntary bankruptcy proceedings that are dismissed within [*]; 

(c) an administrative receiver, receiver and manager, interim receiver, custodian, sequestrator, or similar officer is
appointed for such Party; 
 (d) a resolution to wind up such Party is passed at a meeting of the directors or shareholders
of such Party; 
 (e) a resolution shall have been passed by such Party or its directors to make an application for an
administration order or to appoint an administrator for all of such Party’s assets; or 
 (f) such Party makes any
general assignment for the benefit of all of its creditors. 
 “Invalidity Claim” has the meaning set forth in
Section 9.6. 
 “Invoice” means an invoice in a form reasonably acceptable to NewCo and to Novartis. 

“Know-How” means all proprietary or confidential technical information, know-how and data, including inventions (whether patentable or not), discoveries, trade secrets, specifications, instructions, processes, formulae, materials, expertise and other technology for a compound or product
or to its or their manufacture, regulatory approval, pricing and reimbursement approval, development, or commercialization, or methods of assaying or testing a compound or product, and including all biological, chemical, pharmacological,
biochemical, toxicological, physical and analytical, safety, quality control, manufacturing, preclinical and clinical data, instructions, processes, formulae, expertise and information, regulatory filings and copies thereof. 

“Licensed Compound” means the [*] or [*] “Licensed Compounds” accordingly means both [*] and [*]. 

“Licensed IP” means the Licensed Know-How and the Licensed Patents. “Licensed
Know-How” means the Know-How identified on Exhibit B. 

“Licensed Patents” means the Patent Rights identified on Exhibit C, including any Patent Rights or
interests therein added to Exhibit C after the Effective Date in accordance with Section 9.3. 

“Licensed Product” means a prophylactic, therapeutic or diagnostic product incorporating or comprising a Licensed Compound,
or that is Developed using, incorporates, is made through the use of, or embodies Licensed Know-How. 

“[*]” means (a) the Novartis proprietary compound identified as [*] as specifically described on Exhibit
A, [*] and (b) [*]. 

 “[*]” means (a) the Novartis proprietary compound identified as [*] as
specifically described on Exhibit A, [*] and (b) [*]. 
 “[*] Material” means the material identified
on Exhibit D. 
 “[*] Material” means the material identified on Exhibit E. 

“Loss of Market Exclusivity” means, with respect to any Licensed Product in any country, all of the following have occurred
(a) [*]; and (b) [*]. 
 “MAA” means an application for the authorization to market Licensed Product in any country or
group of countries outside the United States, as defined in the Applicable Laws and filed with the Regulatory Authority of a given country or group of countries. 

“Major European Countries” means France, Germany, Italy, Spain, and the United Kingdom. 

“Major Market Country” means the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan. 

“Meeting Hours” means meeting duration hours spent by Novartis employees in direct interaction with NewCo in face-to-face meetings or teleconferences to answer questions related to transferred data and information, independent of the number of Novartis participants attending the
meeting or participating in the phone conference. For the avoidance of doubt, [*]. 
 “Milestones” means the milestones
relating to Licensed Compound and Licensed Product as set forth in Sections 8.3, 8.4, and 8.5. 
 “Milestone Payments”
means the payments to be made by NewCo to Novartis upon the achievement of the corresponding Milestones as set forth in Sections 8.3, 8.4, and 8.5. 

“NDA” means a New Drug Application, as described in the FDA regulations, 21 C.F.R. § 314.50, submitted to the FDA. 

“Net Sales” means [*]: 

“Novartis Material” means the [*] and the [*]. 

“Patent Rights” means 

(a) all patent applications, including any provisional patent applications, in any country; 

(b) any patent application claiming priority from such patent application in (a) or provisional application, including all
divisionals, continuations, substitutions, continuations-in-part, provisionals, converted provisionals and continued prosecution applications; 

 (c) any patent that has issued or in the future issues from any of the
foregoing patent applications, ((a) and (b)), including any utility model, petty patent, design patent, and certificate of invention; 

(d) any re-examinations, reissues, additions, renewals, extensions, registrations,
supplemental protection certificates of any of the foregoing patents or patent applications ((a), (b), and (c)); and 
 (e)
any similar rights, including so-called pipeline protection, or any importation, revalidation, confirmation or introduction patent or registration patent or patent of additions to any such foregoing patent
application or patent. 
 “Party” or “Parties” has the meaning set forth in the preamble. 

“Person” means any individual, partnership, limited liability company, firm, corporation, association, trust, unincorporated
organization or other entity. 
 “Phase II Clinical Trial” means a human clinical trial of a Licensed Compound or Licensed
Product, the principal purpose of which is a determination of safety and efficacy in the target patient population or a similar clinical study prescribed by the Regulatory Authorities, which trial satisfies the requirements of 21 C.F.R.
§312.21(b) (or its equivalent outside the United States). 
 “Phase III Clinical Trial” means a controlled clinical
study of a Licensed Compound or Licensed Product in patients designed to establish efficacy and safety of such Licensed Compound or Licensed Product for the purpose of preparing and submitting an NDA/MAA or supplement to an NDA/MAA for Regulatory
Approval of such Licensed Product, which trial satisfies the requirements of 21 C.F.R. § 312.21(c) (or its equivalent outside the United States). 

“Pricing and Reimbursement Approval” means the authorization or approval of reimbursement in a country or jurisdiction by the
relevant Regulatory Authority, government agency, or other body responsible for such activities in such country or jurisdiction under Applicable Law. 

“Product Marks” has the meaning set forth in Section 9.9. 

“Regulatory Approval” means, with respect to a Licensed Product in any country or jurisdiction, any approval, registration,
license or authorization from a Regulatory Authority in a country or other jurisdiction that is reasonably necessary to market and sell a Licensed Product in such country or jurisdiction. 

“Regulatory Authority” means any governmental authority or agency responsible for authorizing or approving the marketing or
sale of products in a jurisdiction (e.g., the FDA, European Commission, the Japanese Ministry of Health, Labour and Welfare, the Chinese FDA, and corresponding national or regional regulatory agencies or organizations). 

“Regulatory Exclusivity” means, with respect to a Licensed Product in a country, the period of time during which 

 (a) a Party or its Affiliate or Sublicensee has been granted the exclusive
legal right by a Regulatory Authority (or is otherwise entitled to the exclusive legal right by operation of Applicable Law) in such country to market and sell the Licensed Product; or 

(b) the data and information submitted by a Party or its Affiliate, licensee or Sublicensee to the relevant Regulatory
Authority in such country for purposes of obtaining Regulatory Approval and Pricing and Reimbursement Approval may not be disclosed, referenced, or relied upon in any way by a Third Party or such Regulatory Authority (including by relying upon the
Regulatory Authority’s previous findings regarding the safety or effectiveness of the Licensed Product) to support the Regulatory Approval or Pricing and Reimbursement Approval or marketing of any product by a Third Party in such country. 

“Regulatory Filings” means, with respect to a Licensed Compound or Licensed Product, any submission to a Regulatory Authority
of any appropriate regulatory application, and includes any submission to a regulatory advisory board, marketing authorization application, and any supplement or amendment thereto. For the avoidance of doubt, Regulatory Filings will include any IND,
CTA, NDA, MAA or the corresponding application in any other country or group of countries. 
 “Royalty Term” means, on a country-by-country and Licensed Product-by-Licensed Product basis, the period commencing on the
First Commercial Sale of a Licensed Product in a specified country until the latest to occur of: 
 (a) the
expiration of the last to expire Valid Claim of the Licensed Patents that Covers such Licensed Product in such country; 

(b) the expiration of any Regulatory Exclusivity for such Licensed Product in such country; or 

(c) the ten (10) year anniversary of the First Commercial Sale of the Licensed Product in such country. 

“Sales & Royalty Report” means a written report or reports showing each of: 

(a) the Net Sales of each Licensed Product, on a
country-by-country basis, during the reporting period by NewCo, its Affiliates and Sublicensees (in all cases itemizing by category the various deductions taken from
gross to compute Net Sales as set forth in the definition of Net Sales, above); and 
 (b) the royalties payable, in USD,
which will have accrued hereunder with respect to such Net Sales. 
 “Sales Milestones” has the meaning set forth in
Section 8.5(a). 
 “Sales Milestone Payments” has the meaning set forth in Section 8.5(a). 

 “Senior Officers” means, for Novartis, the [*] or his or her designee, and
for NewCo, its [*], or his or her designee. 
 “Shares” has the meaning set forth in Section 8.2. 

“Sublicensee” means a Person, other than an Affiliate of NewCo, that is granted a sublicense under the Licensed IP by NewCo
or its Affiliate(s). 
 “Territory” means worldwide. 

“Third Party” means any Person other than a Party or an Affiliate of a Party. 

“Third Party Infringement” has the meaning set forth in Section 9.5(a). 

“United States” or “US” means the United States of America, its territories and possessions. 

“USD” or “$” means US Dollars. 

“Valid Claim” means 

(a) a claim of an issued and unexpired patent included within the Licensed Patents that: 

(i) Covers the Manufacture, use, offer for sale, sale or import of the relevant Licensed Compound or Licensed Product in the
relevant jurisdiction; 
 (ii) has not been irrevocably or unappealably disclaimed or abandoned, or been held unenforceable,
unpatentable or invalid by a decision of a court or other governmental agency of competent jurisdiction; and 
 (iii) has not
been admitted to be invalid or unenforceable through reissue, disclaimer, or otherwise; or 
 (b) a claim included in a
pending patent application within the Licensed Patents that: 
 (i) would Cover the Manufacture, use, offer for sale, sale or
import of the relevant Licensed Compound or Licensed Product in the relevant jurisdiction if such claim was to issue; and 

(ii) has not been cancelled, withdrawn or abandoned, nor been pending for more than [*]from the earliest priority date to which
such patent application or claim is entitled. 
 1.2 Interpretation. In this agreement unless otherwise specified: 

(a) “includes” and “including” mean, respectively, includes without limitation and including without limitation; 

 (b) a Party includes its permitted assignees and the respective successors in title to
substantially the whole of its undertaking; 
 (c) a statute or statutory instrument or any of their provisions is to be construed as a
reference to that statute or statutory instrument or such provision as the same may have been or may from time to time hereafter be amended or re-enacted; 

(d) words denoting the singular will include the plural and vice versa and words denoting any gender will include all genders; 

(e) the Exhibits and other attachments form part of the operative provision of this Agreement and references to this Agreement shall, unless
the context otherwise requires, include references to the Exhibits and attachments; 
 (f) the headings in this Agreement are for information
only and will not be considered in the interpretation of this Agreement; 
 (g) general words will not be given a restrictive interpretation
by reason of their being preceded or followed by words indicating a particular class of acts, matters or things; 
 (h) references to days
means calendar days unless otherwise indicated; and 
 (i) the terms of this Agreement are the result of negotiations between the Parties,
and this Agreement will not be construed in favor of or against any Party by reason of the extent to which any Party participated in the preparation of this Agreement. 

2. INTELLECTUAL PROPERTY LICENSE 
 2.1
License Grant. Subject to the terms of this Agreement, Novartis and its Affiliates hereby grant to NewCo a license (with the right to sublicense in accordance with Section 2.2) in, to and under the Licensed IP, to research, Develop, make
and have made, use and Commercialize Licensed Compounds and Licensed Products in the Field and in the Territory. Subject to the retained rights set forth in Section 2.3, the license set forth in this Section 2.1 shall be exclusive (even as
to Novartis and its Affiliates) to NewCo. 
 2.2 Sublicense Rights. NewCo may sublicense (through multiple tiers) the license set
forth in Section 2.1 to any Affiliate or Third Party [*], but subject to the applicable terms of this Agreement. NewCo shall provide Novartis with a copy of any such sublicense agreement within [*] after the execution thereof, provided that
such copy may be subject to redaction as NewCo reasonably believes appropriate to protect sensitive financial provisions. Each sublicense of the Licensed IP shall be consistent with the terms of this Agreement (including with respect to
Section 12.2(c)), and NewCo will remain liable for the compliance of its Sublicensees and Affiliates with the terms of this Agreement applicable to Sublicensees and Affiliates. 

2.3 Retained Rights; No Implied Licenses. Except for the licenses expressly granted to NewCo pursuant to this Agreement, Novartis grants
no other rights or licenses, including any other rights or licenses under the Licensed Patents and the Licensed Know-How, or under any other Patent Rights, Know-How or
other intellectual property rights of Novartis, whether by 

 
implication, estoppel or otherwise. Without limiting the generality of the foregoing, except for the tangible materials referenced on Exhibit D and
Exhibit E, neither Novartis nor its Affiliates has any obligation to transfer any tangible materials to NewCo. Novartis, its Affiliates and its and their agents will retain the right to practice the Licensed IP (i) to
perform its obligations and exercise its rights under this Agreement, and (ii) for non-clinical research purposes. 

2.4 Know-How Relating to Other Compounds. NewCo acknowledges that some of the documentation
within the Licensed Know-How that is transferred to NewCo pursuant to this Article 2 may include information or data that is not Licensed Know-How or which relates
to a compound other than Licensed Compounds, and Novartis will [*]. To the extent that information or data relating to a compound other than Licensed Compounds is transferred to NewCo, no license is granted to NewCo to use such information or data
for any purpose or to disclose such information to any Third Party, and such information and data shall be deemed to be Novartis’ Confidential Information and not subject to disclosure pursuant to Section 10.3(b) or otherwise. 

2.5 Section 365(n) of the U.S. Bankruptcy Code. For purposes of Section 365(n) of the U.S. Bankruptcy Code (the
“Code”) and any similar laws in any other country in the Territory, all rights and licenses granted under or pursuant to this Agreement are rights to “intellectual property” (as defined in Section 101(35A) of the
Code). The Parties agree that the licensee of such rights under this Agreement, will retain and may fully exercise all of its protections, rights and elections under the Code and any similar laws in any country in the Territory outside the US. 

3. GOVERNANCE; INFORMATION UPDATES 
 3.1
Alliance Managers. Within [*] after the Effective Date, each Party shall appoint (and notify the other Party of the identity of) a senior representative having a general understanding of pharmaceutical development and commercialization issues
to act as its alliance manager under this Agreement (“Alliance Manager”). The Alliance Managers will (a) [*]; (b) [*] (c) [*] and (d) [*]. 

3.2 Development Plans; Development Reports. 

(a) Within [*] after the Effective Date, NewCo shall provide Novartis with a high level summary development plan setting forth the anticipated
Development activities to be conducted by NewCo, its Affiliates and Sublicensees related to each Licensed Compound and Licensed Product during the following [*] period (a “Development Plan”). No later than [*] after each anniversary
of the Effective Date, until the First Commercial Sale of each Licensed Product, NewCo shall update the Development Plan and provide, in reasonable detail, the anticipated Development activities to be conducted by NewCo, its Affiliates and
Sublicensees during the following [*] period. For clarity, the Development Plan is intended to outline anticipated activities, and the Parties acknowledge that actual Development of Licensed Compounds or Licensed Products may differ from the
Development Plan. 
 (b) On a Licensed Product-by-Licensed
Product basis, [*], during the Agreement Term until the First Commercial Sale of such Licensed Product, NewCo shall provide to Novartis a [*] report [*] (each, a “Development Report”). The Development Report will include sufficient
information to permit Novartis to determine that NewCo is meeting its diligence obligations under Section 5.2(b) and Section 7.2 of this Agreement. 

 3.3 Meetings. During the period commencing on the Effective Date until the First
Commercial Sale of each Licensed Product, the Alliance Managers shall meet (either in person or by teleconference) at least [*], to review the Development Plan and Development Report and to discuss NewCo’s Development activities. 

4. DISCLOSURE OF LICENSED KNOW-HOW & COOPERATION 

4.1 Transfer of Licensed Know-How. Novartis shall provide to NewCo, within [*] after the
Effective Date, a copy (in electronic format if it is available in electronic format or a hard copy upon written request if it is not available in electronic format) of the documentation listed on Exhibit B. The Parties
acknowledge that the transfer by Novartis of such Licensed Know-How will consist of the transfer of data residing in Novartis’ databases, and will not include the transfer of any database architecture.
All documentation within the Licensed Know-How will be provided in the language such documentation was generated and will not be translated. 

4.2 Licensed Know-How Transfer Assistance. 

(a) For [*] after the Effective Date, and upon [*]. If, during such [*], the Parties identify any
Know-How Controlled by Novartis or any of its Affiliates that the Parties reasonably agree is within the scope they intended to list on Exhibit B as of the Effective Date,
the Parties shall cooperate to amend Exhibit B to include such omitted Know-How. For the avoidance of doubt, [*]. In no event will [*]. The Parties’ Alliance Managers
shall agree on the format, timing, and scope of the relevant Licensed Know-How transfer assistance; provided, that not more than [*] Meeting Hours will be provided pursuant to this Section 4.2(a).

 (b) With respect to any additional reasonable assistance that is requested by NewCo (i.e., in excess of the [*] Meeting Hours
described in Section 4.2(a)), (i) the relevant activities will be agreed upon by the Parties in a written task order describing the scope of the agreed upon activities; and (ii) [*]. 

(c) To the extent that the services described in Section 4.2(a) and 4.2(b) require Novartis to engage a Third Party service provider to
perform the services, NewCo shall pay the costs of such activities. 
 (d) For clarity, except as set forth herein and as otherwise agreed to
by the Parties, all assistance pursuant to this Section 4.2 will be provided remotely (e.g., e-mail, telephone or video conferences) and will not require travel by Novartis personnel. 

4.3 Disclaimer of Warranties. NewCo acknowledges that all of the Licensed Know-How transferred
to NewCo pursuant to Section 4.1 and any assistance provided pursuant to Section 4.2 is provided “as is” and without representation or warranty of any kind. [*]. Novartis will have no obligation to update, revise, amend, or
modify any of the Licensed Know-How or assistance provided to NewCo pursuant to this Article 4 or otherwise pursuant to this Agreement. The use of such Licensed Know-How
and assistance in the Development, manufacture and Commercialization of Licensed Compounds and Licensed Products will be [*]. 

 4.4 Third Party Vendors and Service Providers. The Parties acknowledge that Novartis
and its Affiliates will not transfer or assign any agreements that it or they may have with vendors or service providers (e.g., contract research organizations, contract manufacturers, contract clinical trial sites, consultants, etc.)
in connection with the licenses set forth in this Agreement. However, to the extent NewCo intends to engage one or more of such vendors and service providers in connection with the Development or Commercialization of a Licensed Compound or Licensed
Products, [*] Novartis will issue a letter of authorization to enable NewCo to request access to or copies of Licensed Know- How related to the Licensed Compound held by Novartis’ vendors or service providers, [*] and pursuant to separate
written agreements to be negotiated and entered into by and between NewCo and such Third Party vendors or service providers. 
 5. REGULATORY;
DEVELOPMENT 
 5.1 Novartis’ Obligations. NewCo acknowledges that no INDs or Clinical Trial Applications
(“CTA”) (i.e., sponsorship of the Regulatory Filings themselves) have been filed by or on behalf of Novartis or its Affiliates with respect to a Licensed Compound or a Licensed Product, and no such Regulatory Filings will be
transferred to NewCo. 
 5.2 NewCo’s Obligations. 

(a) From and after the Effective Date, [*] responsible for all regulatory matters arising in connection with the Development of Licensed
Compounds and Licensed Products [*]. 
 (b) NewCo will itself, or through its Affiliates or Sublicensees, use Commercially Reasonable Efforts
to Develop and seek Regulatory Approval (and, if applicable, Pricing and Reimbursement Approval) for at least one Licensed Product in (i) the United States, (ii) all Major European Country, and (iii) Japan. 

5.3 Global Safety Database. NewCo shall establish, hold and maintain the global safety databases for each Licensed Product (the
“Global Safety Database”) into which it shall enter information on all adverse events concerning the Licensed Product occurring anywhere in the world in accordance with Applicable Law. 

6. MATERIAL TRANSFER; MANUFACTURING. 
 6.1
Description of Novartis Material. The [*] and [*] are each to be transferred by Novartis to NewCo is set forth on Exhibit D and Exhibit E, respectively. The Parties anticipate that the
Novartis Material will be transferred to NewCo promptly after the Effective Date as further described in this Article 6. 
 6.2 Transfer
of Novartis Material. Within [*] after the Effective Date, as outlined in Exhibit D and Exhibit E, Novartis will make available for pick-up ([*]) the
Novartis Materials specifically identified on each of Exhibit D and Exhibit E, in the form and quantities set forth on each of Exhibit D and Exhibit
E and as such Novartis Material then exists, from Novartis’ facilities where such Novartis Material is currently stored. The pick-up of the Novartis Material must be completed
within [*] after the date that Novartis notifies NewCo that such Novartis Material is available for pick up. Any Novartis Material not picked up by the end of such [*] period may be disposed of by Novartis [*]. 

 6.3 Documentation and Transfer Process for Novartis Material. In connection with the
transfer of the Novartis Material as described in Section 6.2, the following shall apply: 
 (a) Novartis will share with NewCo any
material safety data sheets and customs value information that is readily available to Novartis (and not otherwise available to NewCo), as is reasonably necessary to permit NewCo to pick up the Novartis Material; 

(b) NewCo will be solely responsible for any re-testing associated with the Novartis Material prior to
use; 
 (c) NewCo will be responsible for all documentation, licenses, customs clearance, costs, etc. that are needed for and related
to the pick-up, transport, and subsequent delivery of the Novartis Material to its destination as determined by NewCo; 

(d) Unless Novartis agrees otherwise in writing, the Novartis Material will be picked up in [*]; and 

(e) the Novartis Material made available by Novartis will only be used according to its specifications, especially release specifications, and
in accordance with Applicable Laws, and Novartis will have no further obligation with respect to the Novartis Material. 
 6.4 ALL
NOVARTIS MATERIAL TRANSFERRED TO NEWCO PURSUANT TO THIS AGREEMENT [*] EFFECTIVE AS OF THE DATE OF TRANSFER, AND WITHOUT REPRESENTATION OR WARRANTY OF ANY KIND. NOVARTIS AND ITS AFFILIATES HEREBY [*]. 

6.5 Manufacturing. From and after the Effective Date, NewCo will be solely responsible for and will, subject to the terms of this
Agreement, have final decision-making authority with respect to the manufacturing of Licensed Compounds and Licensed Products, [*]. 
 7.
COMMERCIALIZATION 
 7.1 Commercialization. NewCo will be solely responsible for all aspects of Commercialization of Licensed
Products, including planning and implementation, distribution, booking of sales, pricing, and reimbursement. 
 7.2 Efforts. NewCo
will itself, or through its Affiliates or Sublicensees, use Commercially Reasonable Efforts to Commercialize at least one Licensed Product (i) in the United States, (ii) all Major European Countries, and (iii) Japan. 

8. FINANCIAL PROVISIONS 
 8.1 Upfront
Payment by NewCo. NewCo shall make a one-time payment to Novartis in the amount of three hundred fifty thousand U.S. Dollars (USD $350,000) via wire transfer within [*] after the Effective Date. 

 8.2 Grant of Equity. In partial consideration of the rights granted NewCo under this
Agreement, NewCo shall issue to Novartis up to an aggregate of 6,383,142 shares of Series A-1 Preferred Stock of NewCo (subject to appropriate adjustment in the event of any stock dividend, stock split,
combination or other similar recapitalization with respect to the Series A-1 Preferred Stock) (the “Shares”), pursuant to and subject to the execution by Novartis of an investment letter (in
the form attached hereto as Exhibit F) and subject to the execution by Novartis of the investor rights agreement, voting agreement and right of first refusal and co-sale agreement entered into by
the purchasers in a concurrent financing transaction conducted by NewCo (the “Financing Transaction”). 
 8.3 Development
Milestone Payments. 
 (a) In further consideration of the rights and licenses granted to NewCo hereunder, upon achievement of each of
the Milestones set forth below (each a “Development Milestone”) by or on behalf of NewCo, its Affiliates or Sublicensees, the corresponding Milestone Payment (a “Development Milestone Payment”) will be
payable to Novartis in USD: 
  

									
	 Development Milestone
	  	Development Milestone
Payment
(USD)	 
	  	[*]
Licensed
Compound	 	 	[*]
Licensed
Compound	 
	 [*]
	  	 	[	*] 	 	 	[	*] 
	 [*]
	  	 	[	*] 	 	 	[	*] 
	 [*]
	  	 	[	*] 	 	 	[	*] 
	 [*]
	  	 	[	*] 	 	 	[	*] 
	 [*]
	  	 	[	*] 	 	 	[	*] 
	 [*]
	  	 	[	*] 	 	 	[	*] 
	 [*]
	  	 	[	*] 	 	 	[	*] 

 (b) Each Development Milestone Payment in the table above will be paid not more than once for each of the [*]
Licensed Compound and [*] Licensed Compound and will be deemed earned as of the first achievement of the corresponding Milestone by the indicated Licensed Compound or Licensed Product comprising the indicated Licensed Compound. NewCo will provide
Novartis with written notice of the achievement of each Milestone within [*] after such Milestone is achieved by or on behalf of NewCo, its Affiliates or their respective Sublicensee(s), and the relevant Development Milestone Payment will be paid by
NewCo within [*] after such Milestone is achieved. 

 [*]Upon achievement of the [*], Novartis may, at its sole discretion, elect to receive the
corresponding Milestone Payment [*] 
 (c) If any of the Commercialization Milestones in Section 8.4(a) below are achieved for a given
Licensed Product with respect to an Indication but one or more of the Development Milestones have not been achieved for such Licensed Product (or the corresponding Licensed Compound) for the same Indication, those skipped Development Milestones will
be deemed to have been achieved at the same time the Commercialization Milestone is achieved. 
 8.4 Commercialization Milestone
Payments. 
 (a) In further consideration of the rights and licenses granted to NewCo hereunder, upon achievement of each of the
Milestones set forth below (each a “Commercialization Milestone”) by or on behalf of NewCo, its Affiliates or Sublicensees, the corresponding Milestone Payment (a “Commercialization Milestone Payment”) will
be payable to Novartis in USD: 
  

					
	 Commercialization Milestone
	  	Commercialization
Milestone Payment
(USD)	 
	 [*]
	  

	 [*]
	  	 	[	*] 
	 [*]
	  	 	[	*] 
	 [*]
	  	 	[	*] 
	 [*]
	  

	 [*]
	  	 	[	*] 
	 [*]
	  	 	[	*] 
	 [*]
	  	 	[	*] 
	 [*]
	  

	 [*]
	  	 	[	*] 
	 [*]
	  	 	[	*] 
	 [*]
	  	 	[	*] 

 (b) Each Commercialization Milestone Payment in the table above will, if the corresponding Milestone is
achieved, be paid (i) once as of the first achievement of the corresponding Milestone by a Licensed Product comprising a [*] Licensed Compound; and (ii) once as of the first achievement of the corresponding Milestone by a Licensed Product
comprising a [*] Licensed Compound. NewCo shall provide Novartis with written notice of the achievement of each Milestone within [*] after such Milestone is achieved by or on behalf of NewCo, its Affiliates or their respective Sublicensee(s), and
the relevant Commercialization Milestone Payment shall be paid to Novartis by NewCo within [*] days after such written notice. 

 8.5 Sales Milestone Payments. 

(a) NewCo shall make each of the following [*] Milestone Payments for sales (the “Sales Milestone Payments”) when worldwide,
aggregate Net Sales of all Licensed Products by or on behalf of NewCo, its Affiliates or Sublicensees in a given Calendar Year first meets the corresponding Net Sales thresholds set forth in the chart below (such thresholds, the “Sales
Milestones”): 
  

					
	 Calendar Year Net Sales Milestones (in USD)
	  	Sales Milestone
Payment
(in USD)	 
	 [*]
	  	 	[	*] 
	 [*]
	  	 	[	*] 

 (b) Each Sales Milestone Payment in the table above will be paid not more than once, and will be deemed earned
as of the first achievement of the corresponding Sales Milestone. NewCo shall provide Novartis with written notice of the achievement of each Sales Milestone after the end of the Calendar Quarter in which such Sales Milestone is achieved
concurrently with the Sales & Royalty Report for such Calendar Quarter by or on behalf of NewCo, its Affiliates or their respective Sublicensee(s), and the corresponding Sales Milestone Payment shall be paid to Novartis by NewCo
concurrently with the payment of royalties for such Calendar Quarter. 
 8.6 Royalty Payments. 

(a) Royalty Rates. During the applicable Royalty Term, NewCo shall make royalty payments to Novartis based on Calendar Year Net Sales of
Licensed Products in the Territory by NewCo, its Affiliates and Sublicensees at the applicable rates set forth below. 
  

					
	 Aggregate Calendar Year Net Sales of Licensed

Products in the Territory
	  	Royalty
Rate	 
	 [*]
	  	 	[	*] 
	 [*]
	  	 	[	*] 
	 [*]
	  	 	[	*] 

 (b) Royalties will be payable on a Licensed Product-by-Licensed Product and country-by-country basis during the Royalty Term for each such Licensed Product in such country.
After the expiration of the applicable Royalty Term for a Licensed Product in a country, the licenses granted to NewCo pursuant to this Agreement with respect to such Licensed Product in such country will continue in effect, but will become fully paid-up, royalty-free, transferable, perpetual and irrevocable. 
 (c) If, during the Royalty Term, the
relevant Licensed Product is (a) not covered by a Valid Claim in the applicable country, or (b) there is a Loss of Market Exclusivity in such country, then for so long as there is (i) no Valid Claim in such country during the Royalty
Term, or (ii) there is a Loss of Market Exclusivity in such country during the Royalty Term, then the royalty rates in such country for such Licensed Product will be reduced to [*] of the rates set forth in the table above. 

(d) If NewCo determines that it is necessary to obtain a license to one or more patents owned or controlled by a Third Party that cover the
manufacture, use, or sale of a Licensed Product, NewCo will be entitled to obtain such license on commercially reasonable terms and will be further entitled [*]. 

(e) [*]. 
 (f) Within [*] after
each Calendar Quarter during the Agreement Term after the First Commercial Sale of a Licensed Product, NewCo shall provide a Sales & Royalty Report to Novartis. Novartis shall submit an Invoice to NewCo with respect to the royalty amount
shown therein. NewCo shall pay such royalty amount to Novartis within [*] after receipt of the Invoice. 
 8.7 Payments. 

(a) All payments from NewCo to Novartis will be made by wire transfer in USD to the credit of such bank account as may be designated by
Novartis in this Agreement or in writing to NewCo. Any payment which falls due on a date which is not a business day in the location from which the payment may be made shall occur on the next succeeding business day in such location. Unless
otherwise provided in this Agreement, all payment terms will be [*]. 
 (b) All payments under this Agreement will be payable in USD. When
conversion of payments from any foreign currency is required to be undertaken by NewCo, the US Dollar equivalent will be calculated using NewCo’s then-current standard exchange rate methodology as applied in its external reporting. If
there is no standard exchange rate methodology applied by NewCo in its external reporting in accordance with NewCo’s Accounting Standards, then any amount in a currency other than USD shall be converted to US Dollars using the exchange rate
most recently quoted in the Wall Street Journal in New York as of the last business day of the applicable Calendar Quarter. 
 (c)
Novartis will pay any and all taxes levied on account of any payments made to it under this Agreement. If any taxes are required to be withheld by NewCo, NewCo will: (i) [*]; (ii) [*]; (iii) [*]; and (iv) [*]. Each Party will reasonably assist
the other Party in lawfully claiming exemptions from or minimizing such deductions or withholdings under double taxation laws or similar circumstances. 

 (d) Without limiting any other rights or remedies available to Novartis hereunder, if NewCo
does not pay any amount due on or before the due date, any such payment shall bear interest at a rate of [*] set by Bank of America and most recently published in the Wall Street Journal (Eastern US edition) as of the date the payment was due or the
highest rate permitted by law (whichever is lower), computed from the date such payment was due until the date NewCo makes the payment. 

8.8 Records and Audit Rights. 

(a) NewCo will keep, and will require its Affiliates and Sublicensees to keep, complete, true and accurate books and records in accordance with
its Accounting Standards in relation to Milestones, Net Sales and royalties payable to Novartis hereunder with respect to Licensed Compounds and Licensed Products. NewCo will keep, and will require its Affiliates, licensees and Sublicensees to keep,
such books and records for at least [*] after the Calendar Quarter to which they pertain. 
 (b) Novartis may, upon [*] prior written notice
to NewCo, appoint an internationally-recognized independent accounting firm (which is reasonably acceptable to NewCo) (the “Auditor”) to inspect the relevant reports, statements, records or books of accounts (as applicable) of NewCo
or its Affiliates, licensees or Sublicensees to verify the accuracy of any Sales & Royalty Report. Before beginning its audit, the Auditor will execute an undertaking reasonably acceptable to NewCo by which the Auditor will keep
confidential all Confidential Information reviewed during such audit. The Auditor will only have the right to disclose to Novartis its conclusions regarding any payment owed under this Agreement. 

(c) NewCo will, and will require its Affiliates and Sublicensees to, make their records available for inspection by such Auditor during regular
business hours at such place or places where such records are customarily kept, upon receipt of reasonable advance notice from Novartis. The records will be reviewed solely to verify the accuracy of the Sales & Royalty Reports. Such
inspection right will not be exercised more than once in any Calendar Year and not more frequently than once with respect to records covering any specific period of time. Novartis will only be entitled to audit the relevant books and records of
NewCo relating to a Sales & Royalty Report for a period of [*] after receipt of the applicable Sales & Royalty Report. Novartis will hold in confidence all Confidential Information received and all Confidential Information learned
in the course of any audit or inspection, except to the extent necessary to enforce its rights under this Agreement or if disclosure is required by Applicable Law. 

(d) The Auditor will provide its audit report and basis for any determination to NewCo at the time such report is provided to Novartis, before
it is considered final. NewCo will have the right to request a further determination by such Auditor as to matters which NewCo disputes within [*] after receipt of such report. NewCo will provide Novartis and the Auditor with a reasonably detailed
statement of the grounds upon which it disputes any findings in the audit report and the Auditor will undertake to complete such further determination within [*] after the dispute notice is provided, which determination will be limited to the
disputed matters. Any matter that remains unresolved will be resolved in accordance with the dispute resolution procedures contained in Section 15.5. 

 (e) If the final result of the inspection reveals an undisputed underpayment or overpayment
by NewCo, the underpaid or overpaid amount will be settled promptly. 
 (f) [*]. 

8.9 No Projections. Novartis and NewCo acknowledge that nothing in this Agreement will be construed as representing an estimate or
projection of anticipated sales of any Licensed Product, and that the Milestones and Net Sales levels set forth above or elsewhere in this Agreement or that have otherwise been discussed by the Parties are merely intended to define the Milestone
Payments and royalty obligations to Novartis if the applicable Milestones or Net Sales levels are achieved. NEWCO MAKES NO REPRESENTATION OR WARRANTY, EITHER EXPRESS OR IMPLIED, THAT IT WILL BE ABLE TO SUCCESSFULLY COMMERCIALIZE ANY LICENSED
PRODUCT OR, IF COMMERCIALIZED, THAT ANY PARTICULAR NET SALES LEVEL OF SUCH LICENSED PRODUCT WILL BE ACHIEVED. 
 9. Intellectual Property. 

9.1 Inventions and Know-How. All inventions, whether or not reduced to practice, and Know-How arising from NewCo’s activities under this Agreement, including activities conducted by or on behalf of NewCo, its Affiliates or Sublicensees, including any Patent Rights claiming such inventions that
arise from such activities after the Effective Date, will be owned by NewCo. 
 9.2 Ownership of Results and Data. All data and
results arising from NewCo’s activities under this Agreement, including activities conducted by or on behalf of NewCo, its Affiliates or Sublicensees, including Development, clinical and regulatory data and information generated for regulatory
purposes relating to Licensed Compound or Licensed Product will be owned by NewCo. 
 9.3 Patent Rights Claiming or Otherwise Supported by
Licensed Know-How. NewCo shall have the right to use and disclose Licensed Know-How to support applications for Patent Rights beyond those licensed to NewCo
hereunder as of the Effective Date. To the extent any such Patent Rights claim inventions as to which Novartis or any of its personnel are inventors, either solely or jointly with NewCo personnel, Novartis shall be a sole or joint owner thereof, as
applicable, and Novartis’ ownership interest therein shall be automatically included in the Licensed Patents and licensed to NewCo pursuant to Section 2.1. The Parties shall update
Exhibit C accordingly, provided that, such interests shall be included in the Licensed Patents whether or not such updating occurs. To the extent any
such Patent Rights claim only inventions as to which only NewCo and/or its personnel are inventors, such Patent Rights shall be solely owned by NewCo. 

9.4 Patent Prosecution and Maintenance After the Effective Date. NewCo will control prosecution and maintenance of the Licensed Patents
[*], using counsel reasonably acceptable to Novartis. NewCo will keep Novartis informed of matters relating to the prosecution and maintenance of the Licensed Patents, and will provide Novartis with copies of documents relevant to such prosecution
and maintenance in sufficient time. With respect to communications issued by patent offices concerning the Licensed Patents, NewCo will notify Novartis of said 

 
communications no later than [*] after their issuance. With respect to documents to be filed at patent offices concerning Licensed Patents, NewCo will notify Novartis no later than [*] prior to
the filing of such documents to allow for review and comment by Novartis, and NewCo will reasonably consider all of Novartis’ comments in good faith. NewCo will notify Novartis of any decision not to continue to pay the expenses of prosecution
and maintenance of any Licensed Patent, which notice must be delivered [*] prior to any payment due date or the relevant action’s due date. Novartis will provide NewCo, at NewCo’s expense, with all reasonable assistance and cooperation in
relation to NewCo’s prosecution and maintenance of Licensed Patents, including providing any necessary powers of attorney and any other documents or instruments required therefor. If NewCo determines not to continue to pay the expenses of
prosecution and maintenance of any Licensed Patent, then Novartis, at its sole discretion, shall have the right to continue the prosecution and maintenance of such Licensed Patent in such country. [*]. 

9.5 Third Party Infringement. 

(a) Each Party will promptly notify the other of any infringement by a Third Party of any of the Licensed Patents or misappropriation of any
Licensed Know-How of which it becomes aware, including any filing of an Abbreviated New Drug Application (“ANDA”) in the United States or such similar filing under Applicable Law in
jurisdictions other than the United States. Each Party shall provide the other Party with all available evidence supporting such infringement, suspected infringement, unauthorized use or misappropriation or suspected unauthorized use or
misappropriation (collectively, “Third Party Infringement”). 
 (b) NewCo will have the first right to bring and control any
legal action in connection with the Third Party Infringement relating to any Licensed Patent at its own expense as it reasonably determines appropriate, and Novartis will have the right, at its own expense, to be represented in any such action by
counsel of its own choice. If NewCo fails to bring an action or proceeding with respect to such Third Party Infringement of any Licensed Patent (i) within [*] after the notice of alleged infringement (or [*] after NewCo receives
the relevant ANDA notification), or (ii) prior to [*] before the time limit, if any, set forth in the Applicable Laws for the filing of such actions, whichever occurs first, Novartis will have the right to bring and control any
such action at its own expense and by counsel of its own choice, and NewCo will have the right, at its own expense, to be represented in any such action by counsel of its own choice. 

(c) At the request of the Party controlling the Third Party Infringement claim, the other Party will provide assistance in connection
therewith, including by executing reasonably appropriate documents, access to such Party’s employees, cooperating reasonably in discovery and joining as a party to the action if required. 

(d) In connection with any such proceeding, neither Party will enter into any settlement admitting the invalidity of, or otherwise impairing
such Party’s rights in, the Licensed IP without the prior written consent of the other Party, which will not be unreasonably withheld or delayed. 

(e) Any recoveries resulting from such an action relating to a Third Party Infringement will be first applied against payment of each
Party’s costs and expenses in connection therewith. If NewCo brought such action, the remainder of such recoveries will be considered lost profits damages attributable to the sale of Licensed Product in the Territory, and NewCo shall pay
royalties to Novartis with respect to the imputed Net Sales upon which such lost profits were determined. If Novartis brought such action, the remainder will be allocated [*]. 

 9.6 Third Party Patent Invalidity Claim. If a Third Party at any time asserts a claim
that any Licensed Patent is invalid or otherwise unenforceable (an “Invalidity Claim”), whether as a defense in an infringement action brought by a Party pursuant to Section 5, in a declaratory judgment action or any patent
office proceeding anywhere in the world (e.g., inter-partes review or European opposition), NewCo shall have the first right, but not the obligation, to defend such Invalidity Claim and Novartis shall cooperate with NewCo in preparing and
formulating a response to such Invalidity Claim. If NewCo does not defend an Invalidity Claim brought against a Licensed Patent, Novartis may defend such Invalidity Claim and the coordination provisions of Section 9.5(c) will apply to such
Invalidity Claim, mutatis mutandis as they apply to Third Party Infringement suits. No Party may, without the consent of the other Party, settle or compromise any Invalidity Claim in any manner which would (a) have an
adverse effect on such other Party’s rights or obligations hereunder or (b) be an admission of liability on behalf of the other Party (provided, however, that the Party asserting or defending such suit may
settle such suit without such consent if such settlement involves only the receipt of money from, or the payment of money to, such Third Party and the Party settling such suit makes all such payments to such Third Party). To the extent an Invalidity
Claim is raised as a defense in an infringement action brought by a Party pursuant to Section 5, the expense provisions of Section 5 will apply and counsel to the Party controlling the infringement action shall act as the ministerial
liaison with the court. 
 9.7 NewCo Patent Invalidity Claim. The Parties have determined the value of the Licensed IP based on their
understanding of the validity and enforceability of the relevant Licensed Patents and Licensed Know-How. If NewCo at any time asserts an Invalidity Claim in a declaratory judgment action or any patent office
proceeding anywhere in the world against a Licensed Patent and such challenge does not result in a material diminution of the scope of the relevant Licensed Patent, i.e., to exclude a [*] or [*] from its scope, then the terms of this Agreement shall
continue in full force and effect, but all payment amounts set forth in Section 8.3, Section 8.4, Section 8.5, and Section 8.6 shall be multiplied by [*]. 

9.8 Defense of Infringement Claims of Licensed IP. If any Third Party asserts a claim, demand, action, suit or proceeding against a
Party (or any of its Affiliates), alleging that any Licensed Product manufactured or sold, or the use or practice of the Licensed IP, by or on behalf of NewCo or any of its Affiliates or Sublicensees infringes, misappropriates or violates the
intellectual property rights of any Person (any such claim, demand, action, suit or proceeding being referred to as an “Infringement Claim”), the Party first having notice of the Infringement Claim shall promptly notify the other
Party thereof in writing specifying the facts, to the extent known, in reasonable detail and the following shall apply: 
 (a) In the case of
any such Infringement Claim against either Party individually or against both Novartis and NewCo, in each case, with respect to the Licensed Product, NewCo shall assume control of the defense of such Infringement Claim. Novartis, [*] and if required
by Applicable Law, will join in any such litigation at NewCo’s expense, and in any event will reasonably cooperate with NewCo at NewCo’s expense. Novartis will have the right to consult with NewCo concerning such Infringement Claim and to
participate in and be represented by independent counsel in any litigation in which NewCo is a party, at its own expense. NewCo shall not have the right to settle any Infringement Claim without the written consent of Novartis (provided,
however, that NewCo may settle such suit without such consent if such settlement involves only the payment of money and NewCo makes all such payments). 

 (b) During the period in which such Infringement Claim is pending and following the
resolution thereof, NewCo shall bear all costs incurred in connection therewith (including litigation costs, attorneys’ fees, costs of settlement) including damage awards, and any other payment resulting therefrom. 

9.9 Trademarks. NewCo will have the right to brand the Licensed Products using NewCo related trademarks and any other trademarks and
trade names it Controls and determines appropriate for Licensed Products, which may vary by country or within a country (“Product Marks”). NewCo will own all rights in the Product Marks and register and maintain the Product Marks in
the countries and regions it determines reasonably necessary. 
 9.10 Patent Extensions. 

[*], Novartis will cooperate in obtaining patent term restoration (including under the Drug Price Competition and Patent Term Restoration Act),
supplemental protection certificates or their equivalents, and patent term extensions with respect to Licensed Patents in any country or region where applicable. [*]. 

(a) As between the Parties, NewCo shall have the first right to determine whether or not to seek a patent term restoration, supplemental
protection certificates or their equivalents, and patent term extensions with respect to Licensed Patents in any country or region where applicable. If NewCo decides not to apply for such extension with respect to a Licensed Patent, NewCo will
provide Novartis with at least [*] notice prior to the relevant application deadline, and Novartis will have the right to apply to extend the term of such Licensed Patent; provided, however, that Novartis will give NewCo prior written
notice before doing so, with sufficient time for NewCo to provide its input which shall be considered in good faith by Novartis with respect to the extension of any Licensed Patents, provided further, however, Novartis shall not have the
right to designate a Licensed Patent for patent term extension based on a Regulatory Approval obtained by NewCo or any of its Affiliates or Sublicensees if NewCo or the applicable Affiliate or Sublicensee has elected to seek extension of a Patent
Right other than a Licensed Patent based on such Regulatory Approval and patent term extensions of more than one patent cannot be obtained in the applicable jurisdiction based on such Regulatory Approval. 

10. CONFIDENTIALITY 
 10.1 Duty of
Confidence. 
 (a) Subject to the other provisions of this Article 10, all Confidential Information disclosed by a Party or its
Affiliates under this Agreement will be maintained in confidence and otherwise safeguarded by the recipient Party. The recipient Party may only use the Confidential Information for the purposes of this Agreement and pursuant to the rights granted to
the recipient Party under this Agreement. Subject to the other provisions of this Article 10, each Party will hold as confidential such Confidential Information of the other Party or its Affiliates in

 
the same manner and with the same protection as such recipient Party maintains its own confidential information. Subject to the other provisions of this Article 10, a recipient Party may only
disclose Confidential Information of the other Party to employees, agents, contractors, consultants and advisers of the Party and its Affiliates and Sublicensees and to Third Parties to the extent reasonably necessary for the purposes of, and for
those matters undertaken pursuant to, this Agreement; provided that such Persons are bound to maintain the confidentiality of the Confidential Information in a manner consistent with the confidentiality provisions of this Agreement. 

(b) With respect to Novartis’ obligations under this Article 10, the Licensed Know- How will be considered Confidential Information of
NewCo during the Agreement Term (and any period thereafter during which NewCo’s license rights hereunder survive beyond the Agreement Term), and Novartis will maintain in confidence and otherwise safeguard such Licensed Know-How as such in accordance with this Article 10 (it being understood that the exception in Section 10.2(b) will not apply to Novartis with respect to Licensed
Know-How). 
 10.2 Exceptions. The obligations under this Article 10 will not apply to any
information to the extent the recipient Party can demonstrate by competent evidence that such information: 
 (a) is (at the time of
disclosure) or becomes (after the time of disclosure) known to the public or part of the public domain through no breach of this Agreement by the recipient Party or its Affiliates; 

(b) was known to, or was otherwise in the possession of, the recipient Party or its Affiliates prior to the time of disclosure by the
disclosing Party or any of its Affiliates; 
 (c) is disclosed to the recipient Party or an Affiliate on a
non-confidential basis by a Third Party who is entitled to disclose it without breaching any confidentiality obligation to the disclosing Party or any of its Affiliates; or 

(d) is independently developed by or on behalf of the recipient Party or its Affiliates, as evidenced by its written records, without reference
to the Confidential Information disclosed by the disclosing Party or its Affiliates under this Agreement. 
 Specific aspects or details of Confidential
Information will not be deemed to be within the public domain or in the possession of the recipient Party merely because the Confidential Information is embraced by more general information in the public domain or in the possession of the recipient
Party. Further, any combination of Confidential Information will not be considered in the public domain or in the possession of the recipient Party merely because individual elements of such Confidential Information are in the public domain or in
the possession of the recipient Party unless the combination and its principles are in the public domain or in the possession of the recipient Party. 

10.3 Authorized Disclosures. 

(a) Neither Party shall issue any press release, trade announcement or make any other public announcement or statement with regard to the
transactions contemplated by this Agreement without the other Parties’ prior written consent, not to be unreasonably withheld or delayed. 

 (b) In addition to disclosures permitted pursuant to Sections 10.1 and 10.2, either Party
may disclose Confidential Information belonging to the other Party or its Affiliates to the extent such disclosure is necessary in the following instances: (i) filing or prosecuting Patent Rights Covering Licensed Products as permitted by this
Agreement; (ii) in connection with Regulatory Filings for Licensed Products; (iii) prosecuting or defending litigation as permitted by this Agreement; (iv) complying with applicable court orders, governmental regulations, or the
inquiries of Regulatory Authorities; (v) in connection with an offering of securities or securities law disclosure requirements if counsel determines that such disclosure is required; (vi) to the extent otherwise necessary or appropriate
in connection with exercising the license and other rights granted to it hereunder; (vii) in the case of NewCo, to bona fide potential investors, licensees, licensors, collaborators, lenders and acquirors/acquirees, and to NewCo’s
consultants and advisors, in connection with a proposed equity or debt financing of such Party, an actual or proposed license, collaboration or similar arrangement, or a proposed acquisition or business combination, so long as such recipients are
bound in writing to maintain the confidentiality of such information in accordance with the terms of this Agreement; or (viii) in the case of NewCo, to bona fide potential Sublicensees or and distributors, so long as such recipients are bound
in writing to maintain the confidentiality of such information in accordance with the terms of this Agreement. 
 (c) If the recipient Party
is required to disclose Confidential Information of the disclosing Party by law or in connection with a bona fide legal process, such disclosure will not be a breach of this Agreement; provided that the recipient Party (i) informs
the disclosing Party as soon as reasonably practicable of the required disclosure; (ii) limits the disclosure to the required purpose; and (iii) at the disclosing Party’s request and expense, assists in an attempt to object to or
limit the required disclosure or to otherwise receive “confidential” or “trade secret” treatment with respect to relevant portions of such disclosure. 

[*]Scientific Publications. NewCo recognizes that the publication of papers regarding the Licensed Compounds and regarding Licensed Know-How generated by or on behalf of Novartis or its Affiliates prior to the Effective Date, including oral presentations and abstracts, may be beneficial to Novartis or NewCo or to the scientific community;
provided that such publications are subject to reasonable controls to protect the Licensed IP. If Novartis intends to make oral or written publications or other disclosures regarding the Licensed Compounds or regarding Licensed Know-How generated prior to the Effective Date (“Publications”), Novartis will provide NewCo with copies of manuscripts or articles, papers, abstracts, oral presentations or any other type of
disclosure at least [*] prior to the first to occur of submission for publication or the date of the planned disclosure or oral presentation. NewCo will have the right to provide comments and suggestions for modifications with respect to any
Publication, and Novartis shall consider and discuss such comments and suggestions with NewCo in good faith. [*], Novartis agrees to withhold submission for publication, or disclosure (including oral presentation) for up to an [*] to allow the
Parties to seek patent protection in accordance with this Agreement, it being understood that Novartis may continue with and allow such Publication after the expiration of such additional [*] 

 10.4 Existing CDA. This Agreement supersedes the Existing CDA; provided,
however, that this shall not limit any remedies available to either Party with respect to any breach of the Existing CDA that occurred prior to the Effective Date. All Confidential Information (as defined in the Existing CDA) exchanged under the
Existing CDA shall be deemed to be Confidential Information under this Agreement and from and after the Effective Date shall be subject to the terms of this Article 10. 

10.5 Ongoing Obligation of Confidentiality. Upon early termination of this Agreement for any reason, each Party and its Affiliates will
immediately return to the other Party or destroy any Confidential Information disclosed by the other Party, except for one copy which may be retained in its confidential files for archive purposes. 

11. TERM AND TERMINATION 
 11.1
Agreement Term. 
 (a) The term of this Agreement will commence on the Effective Date and unless earlier terminated pursuant to this
Article 11, shall expire as follows: (a) on a Licensed Product-by-Licensed Product and
country-by-country basis, upon expiration of the Royalty Term for such Licensed Product in such country; and (b) in its entirety upon the expiration of the Royalty
Term with respect to the last Licensed Product being Developed, manufactured or Commercialized in all countries of the Territory. The period commencing on the Effective Date and ending on the expiration date of this Agreement in its entirety shall
be referred to herein as the “Agreement Term”. 
 (b) Notwithstanding anything herein to the contrary, if this Agreement is
terminated by either Party for any reason or no reason, and a clinical trial of a Licensed Compound or Licensed Product is ongoing as of the effective date of termination, the Parties shall discuss in good faith the appropriate steps to take
regarding the closure or handover of such clinical trial, and in no event will the Party sponsoring the clinical trial be required to breach any Applicable Law or ethical requirement concerning treatment of study subjects. 

11.2 Termination for Cause. If either Novartis or NewCo is in material breach of this Agreement, the
non-breaching Party may give written notice to the breaching Party specifying the claimed particulars of such breach, and if such material breach is not cured or the breaching party has not taken steps as
would be considered reasonable to effectively cure such breach within [*] after such notice (or, within [*] after such notice in the case of a payment breach), the non-breaching Party will have the right (but
not the obligation) thereafter to terminate this Agreement immediately by giving written notice to the breaching Party to such effect; provided that, in the case of such a termination by Novartis based on NewCo’s failure to
satisfy its diligence obligations under Section 5.2 or Section 7.2 as to Japan, such termination right shall be limited to Japan. Any termination by either Party under this Section 11.2 and the effects of termination provided herein
will be without prejudice to any damages or other legal or equitable remedies to which it may be entitled. 

 11.3 Insolvency. If an Insolvency Event occurs, (a) the Party subject to the
Insolvency Event will give immediate (not longer than three (3) business days’) notice to the other Party of such occurrence, and (b) the other Party will have the right to immediately terminate this Agreement by written notice to the
Party that is subject to the Insolvency Event. 
 11.4 Termination by NewCo Without Cause. NewCo may terminate this Agreement without
cause at any time after the Effective Date on ninety (90) days’ prior written notice to Novartis. 
 12. EFFECT OF TERMINATION 

12.1 Termination by NewCo for Cause. Upon termination of this Agreement by NewCo pursuant to Section 11.2: 

(a) the licenses and other rights granted by Novartis to NewCo under the Licensed IP will terminate and NewCo will not have any rights to use
or exercise any rights under the Licensed IP, and the sole right to prosecute and maintain all Licensed Patents shall be transferred to Novartis; and 

(b) within [*] after the effective date of termination (or such later date [*]) NewCo shall return to Novartis or its designee all quantities
of Novartis Material then in its possession or control, [*] and in accordance with Novartis’ shipping and delivery instructions. 
 (c)
Except as set forth in this Section 12.1 and in Section 12.3, the rights and obligations of the Parties hereunder will terminate effective as of the date of such termination. 

(d) Notwithstanding the foregoing, if NewCo has the right to terminate this Agreement pursuant to Section 11.2 based on an uncured breach
by Novartis as set forth above in this Section 12.1, [*], in lieu of such termination, to maintain this Agreement in effect and require the Parties to re- negotiate the financials set forth in Article
8 (excluding Sections 8.1 and 8.2), subject to Expedited Resolution if the Parties are unable to agree within [*] following the effective date of NewCo’s request for such revised financials. 

12.2 Termination by Novartis for Cause or by NewCo Without Cause. Upon termination of this Agreement by Novartis pursuant to
Section 11.2 or 11.3 or by NewCo pursuant to Section 11.4: 
 (a) all licenses and other rights granted by Novartis to NewCo under
the Licensed IP will terminate and NewCo shall not have any rights to use or exercise any rights under the Licensed IP, and the sole right to prosecute and maintain all Licensed Patents shall be transferred to Novartis; 

(b) Within [*] after the effective date of termination (or such later date [*] NewCo shall return to Novartis or its designee all quantities
of Novartis Material then in its possession or control, if any, [*] and in accordance with Novartis’ shipping and delivery instructions; 

 (c) [*], which must be delivered to NewCo not later than [*] after receipt of NewCo’s
or Novartis’ (as applicable) notice of termination, the following provisions shall apply: 
 (i) within [*] after receipt of
Novartis’ written request, NewCo will provide to Novartis a fair and accurate summary report of the status of the Development, manufacture and Commercialization of Licensed Compounds and Licensed Products in each country through the effective
date of termination; 
 (ii) NewCo will grant, and hereby does grant (effective on Novartis’ delivery of the notice pursuant to
Section 12.2(c)), and will cause its Affiliates and their respective Sublicensees to grant, to Novartis and its Affiliates, solely for the research, Development, manufacture and Commercialization of Licensed Products, a perpetual, irrevocable,
exclusive, worldwide, fully paid-up license (subject to the remainder of this Section 12.2(c)), with the right to grant sublicenses, under Patent Rights and
Know-How Controlled by NewCo and its Affiliates, and Sublicensees as of the effective date of termination (in whole or in part, as elected by Novartis), that are related to, and actually used and applied prior
to or as of the date of such termination for the research, Development, manufacture or Commercialization of Licensed Products, to research, Develop, manufacture and Commercialize Licensed Products; provided that with respect to any Patent
Rights and Know-How that is Controlled by NewCo, its Affiliates or Sublicensees pursuant to an agreement with a Third Party, to the extent Novartis elects to obtain a license or sublicense under such Third
Party agreement, Novartis will pay all amounts due under any such Third Party agreement as a result of Novartis’ exercise of the rights granted thereunder; 

(iii) to the extent permitted by Applicable Law, NewCo will, and will cause its Affiliates and its licensees and Sublicensees to, promptly
transfer to Novartis or its designee, solely for the Development, manufacture and Commercialization of Licensed Products, the entire right, title, and interest in and to all Know-How, including preclinical and
clinical data, and all other supporting data, including pharmacology, toxicology, chemistry and biology data, and documented technical and other information or materials Controlled by NewCo and its Affiliates and Sublicensees to the extent related
to the Development, manufacture and Commercialization of Licensed Products; provided that NewCo may retain a single copy of such items for its records as required by Applicable Law; 

(iv) to the extent permitted by Applicable Law, NewCo will, and will cause its Affiliates and Sublicensees to, promptly transfer to Novartis
or its designee all Regulatory Filings, Regulatory Approvals and Pricing and Reimbursement Approvals, the contents of Global Safety Database, records of all interactions with Regulatory Authorities, in each case to the extent related to Licensed
Products, that NewCo, its Affiliates, licensees and Sublicensees Control as of the effective date of such termination; provided, however, that if NewCo is restricted under Applicable Law from transferring ownership of any of the foregoing
items to Novartis or its designee, NewCo will grant, and hereby does grant, to Novartis (or its designee) a right of reference or use to such item. NewCo will take all permitted actions reasonably necessary to effect such transfer or grant of right
of reference or use to Novartis or its designee; 
 (v) to the extent [*]; 

 (vi) Novartis will have the right to purchase from NewCo (in whole or in part) all of the
inventory of Licensed Compounds and Licensed Products held by or on behalf of NewCo or its Affiliates as of the effective date of termination at a price to be determined by the Parties in good faith at NewCo’s actual manufacturing cost,
determined in accordance with NewCo’s Accounting Standards; provided, that NewCo will provide Novartis with assistance in confirming that the inventory of such Licensed Compounds or Licensed Products meets the applicable release
specifications and were maintained under GMP conditions and remain GMP compliant as applicable, including, [*] enabling Novartis to conduct an audit of NewCo’s or its Affiliate’s Third Party holder or supplier of Licensed Compounds or
Licensed Products; 
 (vii) for a period of [*] after the delivery of such notice, NewCo will provide such assistance as may be reasonably
necessary to transfer manufacturing documents and materials that are Controlled by NewCo and its Affiliates (or their subcontractor(s)) and actually used and applied as of the date of such termination in the manufacture of Licensed Products, and
cooperate with Novartis in reasonable respects to transfer to Novartis, or Novartis’ designated contract manufacturer, the manufacturing technologies (including all relevant Know-How) related to the
Licensed Products that are used in the manufacture of the Licensed Products, and Novartis shall reimburse NewCo for such assistance at NewCo’s standard rates; 

(viii) Novartis will thereafter indemnify, defend and hold NewCo and the NewCo Indemnitees harmless in the manner forth in
Section 14.2(a) as if Novartis were NewCo and the NewCo Indemnitees were the Novartis Indemnitees, mutatis mutandis for all claims arising after the effective date of such termination, and NewCo’s indemnification obligations
under that Section 14.2(a) shall thereupon cease for claims arising after the effective date of such termination; 
 (ix) if Novartis
exercises the right to receive any of the reversion rights provided in this Section 12.2(c), in whole or in part, Novartis will pay to NewCo, in consideration of the rights granted to Novartis, an amount to be negotiated by the Parties taking
in to account the relative contribution of the parties to the Development of the Licensed Product and the Licensed Product’s potential commercial value, given its state of development, such negotiation subject to Expedited Resolution if the
Parties are unable to agree on such amount within [*] following Novartis’ exercise of its right to receive such reversion rights; 

(x) to the extent that any personal data, including the Global Safety Database, is to be transferred pursuant to this Section 12.2(c),
the Parties shall amend this Agreement or enter into a new agreement regarding data protection prior to such transfer; and 
 (d) except as
set forth in this Section 12.2 and in Section 12.3, the rights and obligations of the Parties hereunder will terminate as of the date of such termination. 

12.3 Survival. Expiration or termination of this Agreement will not relieve the Parties of any obligation accruing prior to such
expiration or termination. Without limiting the foregoing, Articles 1, 12, 14 and 15, and Sections, 2.3, 2.4, 4.3, 6.4, 8.6, 8.7, 9.1 and 9.2 will survive the expiration or termination of this Agreement for any reason. Article 10 (Confidentiality)
of this Agreement will survive the termination or expiration of this Agreement for a period of [*] after the effective date of termination or expiration (as the case may be). 

12.4 Termination Not Sole Remedy. Termination is not the sole remedy under this Agreement and, whether or not termination is effected
and notwithstanding anything contained in this Agreement to the contrary, all other remedies will remain available except as agreed to otherwise herein. For the avoidance of doubt, nothing in this Agreement shall obligate a Party to terminate this
Agreement if the other Party breaches any obligation of this Agreement, and failure to terminate this Agreement shall not prohibit or modify the recovery of damages available to it pursuant to Section 15.5 or at law. 

 13. REPRESENTATIONS, WARRANTIES AND COVENANTS 

13.1 Representations and Warranties by Each Party. Each Party represents and warrants to the other as of the Effective Date that: 

(a) it is a corporation duly organized, validly existing, and in good standing under the laws of its jurisdiction of formation; 

(b) it has full corporate power and authority to execute, deliver, and perform this Agreement, and has taken all corporate action required by
law and its organizational documents to authorize the execution and delivery of this Agreement and the consummation of the transactions contemplated by this Agreement; 

(c) this Agreement constitutes a valid and binding agreement enforceable against it in accordance with its terms, except as enforceability may
be limited by bankruptcy, fraudulent conveyance, insolvency, reorganization, moratorium and other laws relating to or affecting creditors’ rights generally and by general equitable principles and public policy constraints (including those
pertaining to limitations or exclusions of liability, competition laws, penalties and jurisdictional issues including conflicts of laws); 

(d) all consents, approvals and authorizations from all governmental authorities or other Third Parties required to be obtained by such Party
in connection with this Agreement have been obtained; 
 (e) the execution and delivery of this Agreement and all other instruments and
documents required to be executed pursuant to this Agreement, and the consummation of the transactions contemplated hereby do not and will not (i) conflict with or result in a breach of any provision of its organizational documents;
(ii) result in a breach of any agreement to which it is a party; or (iii) violate any law; and 
 (f) neither such Party nor, to
the actual knowledge of such Party, any employee, agent or subcontractor of such Party involved or to be involved in the Development or manufacture of any Licensed Compound or Licensed Product has been debarred under Subsection (a) or (b) of
Section 306 of the Federal Food, Drug and Cosmetic Act (21 USC §§ 335a). 
 13.2 Covenants by NewCo. NewCo covenants
that: 
 (a) No Person who is known by NewCo (i) to have been debarred under Subsection (a) or (b) of
Section 306 of the Federal Food, Drug and Cosmetic Act (21 USC §§ 335a), or (ii) to be on any of the FDA clinical investigator enforcement lists will be employed by or on behalf of NewCo or its Affiliates or their
respective licensees or Sublicensees, or otherwise participate in the performance of any activities hereunder; 

 (b) Commencing prior to the initiation of clinical trials of any Licensed Product, NewCo
will maintain, general liability insurance with limits not less than those reasonably suited to address claims that could reasonably arise from the Development and Commercialization of pharmaceutical products [*]. [*], NewCo will provide Novartis
with evidence of NewCo’s insurance. NewCo will name Novartis as an additional insured party under such insurance policy, and will provide to Novartis at least [*] prior written notice of any change or cancellation to NewCo’s insurance
program; 
 (c) NewCo will conduct its Development, manufacturing, and Commercialization activities relating to the Licensed Compound and
Licensed Product(s) in accordance with Applicable Law (including data privacy laws, current international regulatory standards, including, as applicable, GMP, GLP, GCP, and other rules, regulations and requirements), and will cause any Affiliates,
licensees, collaborators and Sublicensees to comply with such Applicable Laws; and 
 (d) NewCo will prosecute and maintain the Licensed
Patents in good faith and using Commercially Reasonable Efforts. 
 13.3 Representations and Warranties by Novartis. Novartis
represents and warrants to NewCo as of the Effective Date that: 
 (a) to the knowledge of the Novartis associates responsible for such
matters, Exhibit C sets forth a true, complete and correct list of the Licensed Patents Controlled by Novartis or its Affiliates as of the Effective Date that claim the composition or method of use of
Licensed Compounds; 
 (b) to the knowledge of the Novartis associates responsible for such matters,
Exhibit B sets forth a true, complete and correct list of the Know-How Controlled by Novartis or its Affiliates as of the Effective Date that is
necessary for the Development and Manufacture of the Licensed Compounds described on Exhibit A; 
 (c) Novartis and its
Affiliates are the sole and exclusive owners of the entire right, title and interest in, to and under the Licensed IP, free and clear of all Encumbrances that would interfere with NewCo’s rights; 

(d) Novartis is not a party to any license agreement with a Third Party under which Novartis licenses any of the Licensed IP (except as
provided in Schedule 13.3(d)) and Novartis and its Affiliates have the right to grant the licenses to NewCo under this Agreement; 

(e) each of the Licensed Patents properly identifies each and every inventor of the claims thereof as determined in accordance with the
Applicable Laws of the jurisdiction in which such Licensed Patent is issued or patent application is pending; 
 (f) each Person who has or
has had any rights in or to any Licensed IP has assigned by virtue of employment or written assignment its entire right, title and interest in and to such Licensed IP to Novartis or its Affiliates; 

 (g) there are no amounts that will be required to be paid to a Third Party that arise out of
any agreement to which Novartis or any of its Affiliates is a party, as a result of the Development, manufacture or Commercialization of the Licensed Compounds or Licensed Products; 

(h) to the knowledge of the Novartis associates responsible for such matters, Novartis has filed and prosecuted patent applications within the
Licensed Patents in good faith and complied with all duties of disclosure with respect thereto; 
 (i) Except as set forth on
Schedule 13.3(h), Novartis has not granted to any Third Party, including any academic organization or agency, any license, option or other rights to research, Develop, manufacture, use or Commercialize Licensed Compounds or
Licensed Products; 
 (j) Novartis has not received in writing, and neither Novartis nor its associates responsible for such matters is
aware, of any claims or allegations (including threatened interference actions or oppositions) alleging that the (1) research, Development, registration, manufacture, use or Commercialization of Licensed Compounds or Licensed Products infringes
the Patent Rights or misappropriates the Know-How of any Third Party, (2) that a Third Party has any right or interest in or to the Licensed IP, or (3) that any of the Licensed Patents are invalid or
unenforceable; 
 (k) to the knowledge of the Novartis associates responsible for such matters, there are no facts that could form the basis
for the invalidation or unenforceability of the Licensed Patents; 
 (l) Novartis has not initiated or been involved in any proceedings or
Claims in which it alleges that any Third Party is or was infringing or misappropriating any Licensed IP relating to Licensed Compounds or Licensed Products; 

(m) to the knowledge of the Novartis associates responsible for such matters, there are no activities by Third Parties that would constitute
infringement or misappropriation of the Licensed IP (in the case of pending claims, evaluating them as if issued); and 
 (n) Novartis has
not entered into any agreement with any Third Party that is in conflict with the rights granted to NewCo under this Agreement, and has not taken any action that would in any way prevent it from granting the rights granted to NewCo under this
Agreement, or that would otherwise materially conflict with or adversely affect the rights granted to NewCo under this Agreement. 
 13.4
Covenants of Novartis. Novartis covenants that: 
 (a) it will not grant any interest in the Licensed IP that is inconsistent with
the terms of this Agreement; 
 (b) if, at any time after execution of this Agreement, it becomes aware that it or any employee, agent or
subcontractor of Novartis who participated in the Development or manufacture of a Licensed Compound or Licensed Product is on, or is being added to the FDA Debarment List or to any of the FDA clinical investigator enforcement lists, it will provide
written notice of this to NewCo within [*] after becoming aware of this fact. 

 13.5 No Other Warranties. Except as expressly provided in this Article 13, nothing in
this Agreement shall be construed as a representation made or warranty given by Novartis that it has been or will be successful in prosecuting any Licensed Patents, that any patents will issue based on pending applications or that any such pending
applications or patents issued thereon will be valid. EXCEPT AS EXPRESSLY STATED IN THIS ARTICLE 13, (A) NO REPRESENTATION, CONDITION OR WARRANTY WHATSOEVER IS MADE OR GIVEN BY OR ON BEHALF OF NOVARTIS OR ITS AFFILIATES; AND
(B) ALL OTHER CONDITIONS AND WARRANTIES WHETHER ARISING BY OPERATION OF LAW OR OTHERWISE ARE HEREBY EXPRESSLY EXCLUDED, INCLUDING ANY CONDITIONS AND WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR
PURPOSE OR NON-INFRINGEMENT. 
 14. INDEMNIFICATION; LIABILITY 

14.1 Indemnification by Novartis. Novartis will indemnify and hold NewCo, its Affiliates, and their respective officers, directors and
employees (“NewCo Indemnitees”) harmless from and against any Claims against them to the extent arising or resulting from: 

(a) the breach of any of the obligations, covenants, warranties or representations made by Novartis to NewCo under this Agreement; or 

(b) subject to and except as provided in Sections 4.3, 6.4 and 13.5, any activities conducted by Novartis or its Affiliates or licensees with
respect to the Licensed Compound or Licensed Products prior to the Effective Date; 
 provided, however, that Novartis will not be obliged to so
indemnify, defend and hold harmless the NewCo Indemnitees for any Claims to the extent NewCo has an obligation to indemnify Novartis Indemnitees pursuant to Section 14.2 or to the extent that such Claims arise from the breach, negligence or
willful misconduct of NewCo or the NewCo Indemnitees. 
 14.2 Indemnification by NewCo. NewCo will indemnify and hold
Novartis, its Affiliates, and their respective officers, directors and employees (“Novartis Indemnitees”) harmless from and against any Claims against them to the extent arising or resulting from: 

(a) actions by NewCo, its Affiliates, licensees and Sublicensees, and their respective employees, agents and subcontractors, in connection
with the Development, manufacture or Commercialization of any Licensed Compound or Licensed Products, including, for the avoidance of doubt, all product liability claims (whether arising during Development, manufacture or Commercialization) relating
to any Licensed Compound or Licensed Product (whether pursuant to design defect, manufacturing defect, failure to notify, or otherwise) after the Effective Date; or 

(b) the breach of any of the obligations, covenants, warranties, or representations made by NewCo to Novartis under this Agreement; 

 provided, however, that NewCo will not be obliged to so indemnify, defend and hold harmless the
Novartis Indemnitees for any Claims to the extent Novartis has an obligation to indemnify NewCo Indemnitees pursuant to Section 14.1 or to the extent that such Claims arise from the breach, negligence or willful misconduct of Novartis or the
Novartis Indemnitees. 
 14.3 Indemnification Procedure. 

(a) For the avoidance of doubt, all indemnification claims in respect of an NewCo Indemnitee or Novartis Indemnitee will be made solely by
NewCo or Novartis, respectively. 
 (b) A Party seeking indemnification hereunder (“Indemnified Party”) will notify the
other Party (“Indemnifying Party”) in writing reasonably promptly after the assertion against the Indemnified Party of any Claim or fact in respect of which the Indemnified Party intends to base a claim for indemnification hereunder
(“Indemnification Claim Notice”), but the failure or delay to so notify the Indemnifying Party will not relieve the Indemnifying Party of any obligation or liability that it may have to the Indemnified Party, except to the extent
that the Indemnifying Party demonstrates that its ability to defend or resolve such Claim is adversely affected thereby. The Indemnification Claim Notice will contain a description of the claim and the nature and amount of the Claim (to the extent
that the nature and amount of such Claim is known at such time). Upon the request of the Indemnifying Party, the Indemnified Party will furnish promptly to the Indemnifying Party copies of all correspondence, communications and official documents
(including court documents) received or sent in respect of such Claim. 
 (c) Subject to the provisions of Sections 14.3(d) and 14.3(e), the
Indemnifying Party will have the right, upon written notice given to the Indemnified Party within [*] after receipt of the Indemnification Claim Notice, to assume the defense and handling of such Claim, at the Indemnifying Party’s sole expense,
in which case the provisions of Section 14.3(d) will govern. The assumption of the defense of a Claim by the Indemnifying Party will not be construed as acknowledgement that the Indemnifying Party is liable to indemnify any indemnitee in
respect of the Claim, nor will it constitute a waiver by the Indemnifying Party of any defenses it may assert against any Indemnified Party’s claim for indemnification. If it is ultimately decided that the Indemnifying Party is not obligated to
indemnify or hold an Indemnitee harmless from and against the Claim, the Indemnified Party will reimburse the Indemnifying Party for any and all costs and expenses (including attorneys’ fees and costs of suit) and any losses incurred by the
Indemnifying Party in its defense of the Claim. If the Indemnifying Party does not give written notice to the Indemnified Party, within [*] after receipt of the Indemnification Claim Notice, of the Indemnifying Party’s election to assume the
defense and handling of such Claim, the provisions of Section 14.3(e) will govern. 
 (d) Upon assumption of the defense of a Claim by
the Indemnifying Party: (i) the Indemnifying Party will have the right to and will assume sole control and responsibility for dealing with the Claim; (ii) the Indemnifying Party may, at its own cost, appoint as counsel in connection with
conducting the defense and handling of such Claim any law firm or counsel reasonably selected by the Indemnifying Party; (iii) the Indemnifying Party will keep the Indemnified Party informed of the status of such Claim; and (iv) the
Indemnifying Party will have the right to settle the Claim on any terms the Indemnifying Party chooses; provided, however, that 

 
it will not, without the prior written consent of the Indemnified Party, agree to a settlement of any Claim which could lead to liability or create any financial or other obligation on the part
of the Indemnified Party for which the Indemnified Party is not entitled to indemnification hereunder or which admits any wrongdoing or responsibility for the claim on behalf of the Indemnified Party. The Indemnified Party will cooperate with the
Indemnifying Party and will be entitled to participate in, but not control, the defense of such Claim with its own counsel and at its own expense. In particular, the Indemnified Party will furnish such records, information and testimony, provide
witnesses and attend such conferences, discovery proceedings, hearings, trials and appeals as may be reasonably requested in connection therewith. Such cooperation will include access during normal business hours by the Indemnifying Party to, and
reasonable retention by the Indemnified Party of, records and information that are reasonably relevant to such Claim, and making the Indemnified Party, the Indemnitees and its and their employees and agents available on a mutually convenient basis
to provide additional information and explanation of any records or information provided. 
 (e) If the Indemnifying Party does not give
written notice to the Indemnified Party as set forth in Section 14.3(c) or fails to conduct the defense and handling of any Claim in good faith after having assumed such, the Indemnified Party may, at the Indemnifying Party’s expense,
select counsel reasonably acceptable to the Indemnifying Party in connection with conducting the defense and handling of such Claim and defend or handle such Claim in such manner as it may deem appropriate. In such event, the Indemnified Party will
keep the Indemnifying Party timely apprised of the status of such Claim and will not settle such Claim without the prior written consent of the Indemnifying Party, which consent will not be unreasonably withheld. If the Indemnified Party defends or
handles such Claim, the Indemnifying Party will cooperate with the Indemnified Party, at the Indemnified Party’s request but at no expense to the Indemnified Party, and will be entitled to participate in the defense and handling of such Claim
with its own counsel and at its own expense. 
 14.4 Mitigation of Loss. Each Indemnified Party will take and will procure that its
Affiliates take all such reasonable steps and action as are necessary or as the Indemnifying Party may reasonably require in order to mitigate any Claims (or potential losses or damages) under this Article 14. Nothing in this Agreement will or will
be deemed to relieve any Party of any common law or other duty to mitigate any losses incurred by it. 
 14.5 Special, Indirect and Other
Losses. NO PARTY NOR ANY OF SUCH PARTY’S AFFILIATES SHALL BE LIABLE IN CONTRACT, TORT, NEGLIGENCE BREACH OF STATUTORY DUTY OR OTHERWISE FOR ANY SPECIAL, INDIRECT, INCIDENTAL, PUNITIVE OR CONSEQUENTIAL DAMAGES OR FOR ANY ECONOMIC LOSS OR
LOSS OF PROFITS SUFFERED BY THE OTHER PARTY, EXCEPT TO THE EXTENT ANY SUCH DAMAGES ARE REQUIRED TO BE PAID TO A THIRD PARTY AS PART OF A CLAIM FOR WHICH A PARTY PROVIDES INDEMNIFICATION UNDER THIS ARTICLE 14 OR FOR A BREACH OF ARTICLE 9 OR ARTICLE
10 . 

 15. GENERAL PROVISIONS 

15.1 Assignment. No Party may assign its rights and obligations under this Agreement without the other Party’s prior written
consent, except that either Party may (i) assign its rights and obligations under this Agreement or any part hereof to one or more of its Affiliates; or (ii) assign this Agreement in its entirety to a successor
to all or substantially all of its business or assets to which this Agreement relates. Any permitted assignee will assume all obligations of its assignor under this Agreement. Any attempted assignment in contravention of the foregoing will be void.
Subject to the terms of this Agreement, this Agreement will be binding upon and inure to the benefit of the Parties and their respective successors, heirs and permitted assigns. 

15.2 Extension to Affiliates. NewCo will have the right to extend the rights, immunities and obligations granted in this Agreement to
one or more of its Affiliates. All applicable terms of this Agreement will apply to any such Affiliate to which this Agreement has been extended to the same extent as such terms apply to NewCo. NewCo will remain primarily liable for any acts or
omissions of its Affiliates. 
 15.3 Severability. Should one or more provisions of this Agreement become void or unenforceable as a
matter of law, then this Agreement will be construed as if such provision were not contained herein and the remainder of this Agreement will be in full force and effect, and the Parties will use their commercially reasonable efforts to substitute
for the invalid or unenforceable provision a valid and enforceable provision which conforms as nearly as possible with the original intent of the Parties. 

15.4 Governing Law and Jurisdiction. This Agreement will be governed by and construed under the laws of the State of New York, USA,
without giving effect to the conflicts of laws provision thereof. The United Nations Convention on Contracts for the International Sale of Goods (1980) will not apply to the interpretation of this Agreement. 

15.5 Dispute Resolution. 

(a) In the event of a dispute relating to, arising out of or in any way connected with this Agreement or any term hereof, or the performance
by either Party of its obligations hereunder (a “Dispute”), the Parties will refer the Dispute to the Alliance Managers for discussion and resolution. If the Alliance Managers are unable to resolve the Dispute within [*] after the
Dispute is referred to them, either Party may require that the Parties forward the matter to the Senior Officers (or designees with similar authority to resolve such dispute), who will attempt in good faith to resolve the Dispute. If the Senior
Officers cannot resolve the Dispute within [*] after the matter is referred to them, either Party will be free to initiate the arbitration proceeding set forth in Section 15.5(b) to resolve the matter. 

(b) Any unresolved Disputes between the Parties, other than those expressly resolved pursuant to the Expedited Resolution procedure of
Section 15.6, whether arising before or after termination of this Agreement, will be resolved by final and binding arbitration. Whenever a Party decides to institute arbitration proceedings, it will give written notice to that effect to the
other Party. Arbitration will be held in Boston, Massachusetts, USA, in accordance with the commercial arbitration rules of the International Chamber of Commerce (“ICC”). The arbitration will be conducted by a panel of three
(3) arbitrators appointed in accordance with ICC rules; provided that each Party will, within [*] after the institution of the arbitration proceedings, appoint an arbitrator, and such arbitrators will together, within [*], select
a third arbitrator as the chair of the arbitration panel, and each arbitrator will have significant experience in the biopharmaceutical 

 
industry. If the two initial arbitrators are unable to select a third arbitrator with in such [*] period, the third arbitrator will be appointed in accordance with ICC rules. The arbitrators will
render their opinion within [*] after the final arbitration hearing. No arbitrator (nor the panel of arbitrators) will have the power to award punitive damages, or to award costs and expenses of the proceeding or reasonable attorney’s fees to
either Party under this Agreement and such award is expressly prohibited. Decisions of the panel of arbitrators will be final and binding on the Parties. Judgment on the award so rendered may be entered in any court of competent jurisdiction. 

(c) Notwithstanding Section 15.4 and Section 15.5(b), any dispute, controversy or claim relating to the scope, validity,
enforceability or infringement of any Patent Right Covering the manufacture, use, importation, offer for sale or sale of any Licensed Compound or Licensed Product or of any trademark rights relating to any Licensed Product shall be submitted to a
court of competent jurisdiction in the country in which such Patent Right or trademark rights were granted or arose. 
 15.6 Expedited
Resolution. If a Party exercises its rights under this Agreement to refer a dispute to expedited resolution then the Parties will follow the expedited dispute resolution process in this Section 15.6 (and not the dispute resolution process
in Section 15.5 of this Agreement) (“Expedited Resolution”). The Parties agree and acknowledge that any good faith dispute under Expedited Resolution will not be deemed to be a material breach of this Agreement. The Expedited
Resolution will be fast-track, binding arbitration carried out in accordance with the following (a) the Parties will refer the matter to arbitration before a mutually acceptable independent arbitrator, who shall be experienced in the
pharmaceutical business; (b) each Party will submit its final proposed terms to the other Party at least [*] prior to submission to the independent arbitrator; (c) the independent arbitrator will select between the two sets
of terms (i.e., the independent arbitrator will select the more suitable set of terms submitted by the Parties, and will not propose a third set of terms), and shall render his or her opinion within [*] after the final arbitration hearing; and
(d) the decision of the arbitrator shall be final and binding on the Parties, and shall not be subject to the dispute resolution provisions set forth in Section 15.5 

15.7 Force Majeure. If either Party is prevented from performing its obligations under this Agreement as a result of any contingency
beyond its reasonable control (“Force Majeure”), including any actions of governmental authorities or agencies, war, hostilities between nations, civil commotions, riots, national industry strikes, lockouts, sabotage, shortages in
supplies, energy shortages, fire, floods and acts of nature such as typhoons, hurricanes, earthquakes, or tsunamis, the Party so affected will not be responsible to the other Party for any delay or failure of performance of its obligations
hereunder, for so long as Force Majeure prevents such performance. In the event of Force Majeure, the Party immediately affected thereby will give prompt written notice to the other Party specifying the Force Majeure event complained of, and will
use diligent efforts to cure such failure or omission as soon as is practicable after the occurrence of the Force Majeure event. Notwithstanding the foregoing, if such Force Majeure induced delay or failure of performance continues for more than
[*], either Party may terminate this Agreement upon written notice to the other Party. 
 15.8 Waivers and Amendments. The failure of
any Party to assert a right hereunder or to insist upon compliance with any particular term of this Agreement will not constitute a waiver of that right or excuse a similar subsequent failure to perform any such term by the other Party.

 
No waiver will be effective unless it has been given in writing and signed by the Party giving such waiver. No provision of this Agreement may be amended or modified other than by a written
document signed by authorized representatives of each Party. 
 15.9 Relationship of the Parties. Nothing contained in this Agreement
will be deemed to constitute a partnership, joint venture, or legal entity of any type between Novartis and NewCo, or to constitute one as the agent of the other. Moreover, each Party will not construe this Agreement, or any of the transactions
contemplated hereby, as a partnership for any tax purposes. Each Party will act solely as an independent contractor, and nothing in this Agreement will be construed to give any Party the power or authority to act for, bind, or commit the other. 

15.10 Notices. All notices, consents, waivers, and other communications under this Agreement must be in writing and will be deemed to
have been duly given when: (a) delivered by hand (with written confirmation of receipt); or (b) when received by the addressee, if sent by an internationally recognized overnight delivery service (receipt
requested), in each case to the appropriate addresses set forth below (or to such other addresses as a Party may designate by notice): 
 If
to NewCo: 
 Third Harmonic Bio, Inc. 

c/o Atlas Ventures 
 [*] 

with a required copy to: 
 [*]

 If to Novartis: 
 Novartis
International Pharmaceutical Ltd. 
 [*] 

with a required copy to: 

Novartis Institutes for BioMedical Research, Inc. 

[*] 
 15.11 Further
Assurances. NewCo and Novartis will execute, acknowledge and deliver any and all such other documents and take any such other action as may be reasonably necessary to carry out the intent and purposes of this Agreement. 

15.12 Compliance with Law. Each Party will perform its obligations under this Agreement in accordance with all Applicable Laws. No
Party will, or will be required to, undertake any activity under or in connection with this Agreement which violates, or which it believes, in good faith, may violate, any Applicable Law. 

 15.13 No Third Party Beneficiary Rights. The provisions of this Agreement are for the
sole benefit of the Parties and their successors and permitted assigns, and they will not be construed as conferring any rights to any Third Party (including any third party beneficiary rights). 

15.14 Cumulative Remedies. No remedy referred to in this Agreement is intended to be exclusive, but each will be cumulative and in
addition to any other remedy referred to in this Agreement or otherwise available under law. 
 15.15 Expenses. Except as otherwise
expressly provided in this Agreement, each Party will pay the fees and expenses of its respective lawyers and other experts and all other expenses and costs incurred by such Party incidental to the negotiation, preparation, execution and delivery of
this Agreement. 
 15.16 Entire Agreement. This Agreement, together with its Exhibits and schedules, sets forth the entire agreement
and understanding of the Parties as to the subject matter hereof and supersedes all proposals, oral or written, and all other prior communications between the Parties with respect to such subject matter, including the Existing CDA. In the event of
any conflict between a substantive provision of this Agreement and any Exhibit or schedule hereto, the substantive provisions of this Agreement will prevail. 

15.17 Counterparts. This Agreement may be executed in two or more counterparts, each of which will be deemed an original, but all of
which together will constitute one and the same instrument. Signatures provided by facsimile transmission or in Adobe Portable Document Format (.pdf) sent by electronic mail shall be deemed to be original signatures. 

[Signature Page Follows] 

 IN WITNESS WHEREOF, the Parties, intending to be legally bound, have caused this
Agreement to be executed by their duly authorized representatives as of the Effective Date. 
  

									
	 NOVARTIS INTERNATIONAL

PHARMACEUTIC LTD.
	  		  	THIRD HARMONIC BIO, INC.
					
	By:	  	 /s/ Simone Pfirter
	  	    	  	By:	  	 /s/ Michael Glastone

	Name: Simone Pfirter	  		  	Name: Michael Gladstone
	Title: Authorized Signatory	  		  	Title: Acting Chief Executive Officer
					
	By:	  	 /s/ Sylvain Beltzung
	  		  		  	
	Name: Sylvain Beltzung	  		  		  	
	Title: Authorized Signatory	  		  		  	

  

 EXHIBIT A 

[*] 

 EXHIBIT B 

NOVARTIS KNOW-HOW 

 EXHIBIT D 

 EXHIBIT E 

 EXHIBIT F 

Investment Letter 
 Third Harmonic Bio, Inc. 

400 Technology Square, 10th Floor 

Cambridge, MA 02139 
 Dear Sirs: 

In order to induce Third Harmonic Bio, Inc., a Delaware corporation (the “Company”), to issue and sell to the undersigned
shares (the “Shares”) of Series A-1 Preferred Stock, $0.0001 par value per share, of the Company (the “Series A-1 Preferred Stock”) to
Novartis Institutes for Biomedical Research, Inc. (“Novartis”), as provided hereunder, pursuant to and in satisfaction of the Company’s obligations under that certain License Agreement to be entered into between the Company and
Novartis on or about the date hereof (the “License Agreement”): 
 1. The Company represents, warrants and covenants as follows: 

(a) Share Issuance 

(i) At the First Tranche Closing (as defined in the Series A Preferred Stock Purchase Agreement, by and among the Company and
the Purchasers (as defined therein) (the “Series A Preferred Stock Purchase Agreement”), the Company shall issue to Novartis [•]1 shares of Series A-1 Preferred Stock. 
 (ii) Within ten (10) business days after the Second Tranche
Closing (as defined in the Series A Preferred Stock Purchase Agreement) the Company shall issue to Novartis an additional number of shares of Series A-1 Preferred Stock such that Novartis, immediately
following the Second Tranche Closing and such issuance, will hold fifteen percent (15%) of the Fully Diluted Capitalization of the Company. 

(iii) Within ten (10) business days after the Third Tranche Closing (as defined in the Series A Preferred Stock Purchase
Agreement) the Company shall issue to Novartis an additional number of shares of Series A-1 Preferred Stock such that Novartis, immediately following the Third Tranche Closing and such issuance, will hold
fifteen percent (15%) of the Fully Diluted Capitalization of the Company. 
 Notwithstanding the foregoing, (x) in the event that the
Company issues and sells shares of its preferred stock in a financing transaction in lieu of and prior to conducting the Second Tranche Closing or the Third Tranche Closing, as the case may be (an “Alternative Financing”), then
within ten (10) business days after the closing of such Alternative Financing, the Company shall issue to Novartis an additional number of shares of Series A-1 Preferred Stock such that Novartis,
immediately following the closing of such Alternative Financing and such issuance, will hold fifteen percent (15%) of the Fully Diluted Capitalization of the Company; (y) the Company 

 

	1 	 Note to draft: Novartis to be issued shares representing 15% of the Fully Diluted Capitalization at the first
closing, then the number of shares necessary to maintain that 15% at each closing of the subsequent tranches. 

 
shall have no obligation hereunder to issue to Novartis any Shares (I) following such time as the Company has issued and sold securities having an aggregate purchase price of $30,000,000
since its incorporation (whether pursuant to the Series A Preferred Stock Purchase Agreement, an Alternative Financing or otherwise) or (II) with respect to any securities issued and sold by the Company that generate proceeds in excess of such
$30,000,000; and (z) the Company shall have no obligation hereunder to issue to Novartis more than 6,383,142 Shares (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar
recapitalization with respect to the Series A- 1 Preferred Stock). 
 “Fully Diluted
Capitalization” means the sum of (A) all shares of common stock, $0.0001 par value per share, of the Company (the “Common Stock”) then outstanding, (B) all shares of preferred stock of the Company then
outstanding, (C) all shares of Common Stock issuable upon exercise, conversion or exchange of all convertible securities of the Company then outstanding (including those issued under a stock incentive plan of the Company) and (D) all
shares reserved for issuance under a stock incentive plan of the Company. 
 (b) The Company is not a “pilot program U.S.
business” as that term is defined in 31 C.F.R. § 801.213. 
 (c) The Company does not engage in the design, fabrication,
development, testing, production or manufacture of critical technologies within the meaning of the Defense Production Act of 1950, as amended, including all implementing regulations thereof and has no current intention of engaging in such activities
in the future. 
 (d) The Company has not taken, and has no current intention of taking, any of the following actions: [...] The design,
fabrication, development, testing, production or manufacture of “critical technologies” as defined by 31 C.F.R. § 801.204, as amended. 

(e) If, to the knowledge of the Company, at any time the Company (i) is deemed to be a “pilot program U.S. business” as that
term is defined in 31 C.F.R. § 801.213 or (ii) engages in the design, fabrication, development, testing, production or manufacture of “critical technologies” as defined by 31 C.F.R. § 801.204, as amended, then the Company
shall provide written notice to Novartis within 10 business days of knowledge of such designation or engagement. 
 2. Novartis represents, warrants and
covenants as follows: 
 (a) Novartis is acquiring the Shares, and the shares of Common Stock issuable upon conversion of the Shares
(together with the Shares, the “Securities”) for its own account for investment only, and not with a view to, or for sale in connection with, any distribution of the Securities in violation of the Securities Act of 1933 (the
“Securities Act”), or any rule or regulation under the Securities Act. 
 (b) Novartis has had such opportunity as it has deemed
adequate to obtain from representatives of the Company such information as is necessary to permit it to evaluate the merits and risks of its investment in the Company. 

  
 2 

 (c) Novartis has sufficient experience in business, financial and investment matters to be
able to evaluate the risks involved in the purchase of the Shares and to make an informed investment decision with respect to such purchase. 

(d) Novartis can afford a complete loss of the value of the Securities and is able to bear the economic risk of holding such Securities for an
indefinite period. 
 (e) Novartis understands that (i) the Securities have not been registered under the Securities Act and are
“restricted securities” within the meaning of Rule 144 under the Securities Act; (ii) the Securities cannot be sold, transferred or otherwise disposed of unless they are subsequently registered under the Securities Act or an exemption
from registration is then available; (iii) in any event, the exemption from registration under Rule 144 or otherwise may not be available for at least one year and even then will not be available unless a public market then exists for the
Common Stock, adequate information concerning the Company is then available to the public, and other terms and conditions of Rule 144 are complied with; and (iv) there is now no registration statement on file with the Securities and Exchange
Commission with respect to any stock of the Company and the Company has no obligation or current intention to register the Shares under the Securities Act. 

(f) A legend substantially in the following form will be placed on any certificates representing the Securities: 

“The shares represented by this certificate have not been registered under the Securities Act of 1933, as amended, and may not be sold,
transferred or otherwise disposed of in the absence of an effective registration statement under such Act or an opinion of counsel satisfactory to the corporation to the effect that such registration is not required.” 

(g) Novartis agrees that, in connection with its acquisition of the Shares, Novartis will become a party to, bound by, and subject to the
terms of (i) the Voting Agreement, dated on or about the date hereof, by and among the Company and the Stockholders named therein, as may be further amended and/or restated from time to time; (ii) the Right of First Refusal and Co-Sale Agreement, dated on or about the date hereof, by and among the Company, the Investors and the Common Holders named therein, as may be further amended and/or restated from time to time; and (iii) the
Investors’ Rights Agreement, dated on or about the date hereof, by and among the Company, the Investors and the Common Holders named therein, as may be further amended and/or restated from time to time (the “Investors’ Rights
Agreement”). 
 In addition, as long as Novartis continues to own all of the Shares issued by the Company to Novartis pursuant to the
License Agreement (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Series A-1 Preferred Stock), the Company
shall invite a representative of Novartis (who shall be reasonably acceptable to the Company’s Board of Directors (the “Representative”) to attend all meetings (in-person, telephonic or
otherwise) of the Board of Directors in a non- voting observer capacity and, in this respect, shall give such Representative copies of all notices, minutes, consents, and other materials that it provides to
its directors, except that the Representative may be excluded from access to any material or meeting or portion thereof if the Board of Directors determines in good faith, that such exclusion is necessary to preserve the attorney-client privilege or
to protect 

  
 3 

 
highly confidential proprietary information (unless covered by an enforceable confidentiality agreement), or that the disclosure of such information would jeopardize the Company’s client or
vendor relationships. Novartis hereby agrees that any confidential information provided to or learned by it in connection with its rights under this letter shall be subject to the confidentiality provisions set forth in the License Agreement. In
addition, the Representative shall be required to execute a confidentiality agreement, in a form reasonably acceptable to the Company. 
 In
addition, the Company shall deliver to Novartis as soon as practicable, but in any event within one hundred fifty (150) days after the end of each fiscal year of the Company, commencing with the fiscal year ending December 31, 2019, (i) a
balance sheet as of the end of such year, (ii) statements of income and of cash flows for such year and (iii) a statement of stockholders’ equity as of the end of such year, all such financial statements audited and certified by
independent public accountants of nationally recognized standing selected by the Company; provided, however, that if the Major Investors (as defined in the Investors’ Rights Agreement) waive the right to receive audited financial
statements under Section 3.1 of the Investors’ Rights Agreement, then the Company shall have no obligation to provide audited financial statements to Novartis pursuant to this paragraph, provided that the Company shall deliver to Novartis
the unaudited items in clauses (i), (ii) and (iii) above in lieu of such audited financial statements. 
 The rights described in the
two preceding paragraphs shall terminate and be of no further force or effect upon (a) such time as less than all of the Shares issued by the Company pursuant to the License Agreement (subject to appropriate adjustment in the event of any stock
dividend, stock split, combination or other similar recapitalization with respect to the Series A-1 Preferred Stock) are held by the Novartis; (b) the consummation of the sale of the Company’s
securities pursuant to a registration statement filed by the Company under the Securities Act in connection with the firm commitment underwritten offering of its securities to the general public; or (c) the consummation of a merger or
consolidation of the Company that is effected (i) for independent business reasons unrelated to extinguishing such rights; and (ii) for purposes other than (A) the reincorporation of the Company in a different state; or (B) the
formation of a holding company that will be owned exclusively by the Company’s stockholders and will hold all of the outstanding shares of capital stock of the Company’s successor. The confidentiality obligations referenced herein will
survive any such termination. 

  
 4 

 IN WITNESS WHEREOF, the parties have executed this Investment Letter as of the dates set
forth below. 
 NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 
  

									
	By:	 	  
	  		  	Date:	  	  

	Name:	 		  		  		  	
	Title:	 		  		  		  	
				
	THIRD HARMONIC BIO, INC.	  		  		  	
					
	By:	 	  
	  		  	Date:	  	  

	Name:	 		  		  		  	
	Title:	 		  		  		  	

 SCHEDULE 13.3(d) 

 SCHEDULE 13.3(h) 

 AMENDMENT TO LICENSE AGREEMENT 

This Amendment to License Agreement (this “Amendment”) is entered into as of April 28, 2020 (the “Amendment
Date”) by and between Novartis International Pharmaceutical Ltd., a for profit corporation with its principal place of business at Lichtstrasse 35, CH-4056 Basel, Switzerland (“Novartis”)
and Third Harmonic Bio, Inc. (hereinafter referred to as “NewCo”). Novartis and NewCo are each referred to individually as a “Party” and together as the “Parties.” 

WHEREAS, NewCo and Novartis are parties to that certain License Agreement effective as of June 28, 2019 (the
“Agreement”); 
 WHEREAS, Novartis has determined that certain Know-How pertaining
to [*], a compound related to Licensed Compounds, was intended to be listed in Exhibit B and included within the Licensed Know-How; 

WHEREAS, Novartis and NewCo have agreed to amend Exhibit B to incorporate such Know-How into the
Licensed Know-How; 
 WHEREAS, Novartis has agreed to transfer a certain quantity of non-GMP grade [*] to NewCo; and 
 WHEREAS, Novartis has determined that the structure of Licensed
Compound [*] should be updated to [*]. 
 NOW, THEREFORE, the Parties agree as follows: 

1. Exhibit A of the Agreement is hereby replaced in its entirety with the Exhibit A attached hereto. 

2. Exhibit B of the Agreement is hereby replaced in its entirety with the Exhibit B attached hereto and the content of such replacement Exhibit B will be
considered to be Licensed Know- How. 
 3. Novartis hereby agrees to transfer to NewCo [*]. Within [*] after the Amendment Date, Novartis will make
available for pick-up [*] the [*] Material as such [*] Material then exists, from Novartis’ facilities where such [*] Material is currently stored. The pick-up of
the [*] Material must be completed within [*] after the date that Novartis notifies NewCo that such [*] Material is available for pick up. Any [*] Material not picked up by the end of such [*] period may be disposed of by Novartis in its sole
discretion. In addition, the provisions of Sections 6.3 and 6.4 of the Agreement will apply mutatis mutandis to the [*] Material. 
 4. This
Amendment is effective upon the Amendment Date and is and will be deemed to be an integral part of the Agreement. 
 5. Any initially capitalized terms not
otherwise defined herein shall have the meanings given in the Agreement. 
 6. Except as expressly amended hereby, all terms of the Agreement shall remain
unchanged and in full force and effect. 

 7. This Amendment may be executed in multiple counterparts, each of which shall be deemed an original, but
all of which together shall constitute one and the same instrument. 
 IN WITNESS WHEREOF, the parties have duly executed this Amendment as
of the Amendment Date. 
  

									
	 NOVARTIS INTERNATIONAL

PHARMACEUTICAL LTD.
	  		  	THIRD HARMONIC BIO, INC.
					
	By:	 	 /s/ Simone Pfirter
	  		  	By:	  	 /s/ Michael Gladstone

	Name: Simone Pfirter	  	    	  	Name: Michael Gladstone
	Title: Head of NIBR General Legal Europe	  		  	Title: President and CEO
			
		  		  	Date: 4/17/20
				
	By:	 	 /s/ Beltzung Sylvain
	  		  	

 Exhibit A 

 Exhibit B 

 SECOND AMENDMENT TO LICENSE AGREEMENT 

This Second Amendment to License Agreement (this “Second Amendment”) is entered into as of March 17, 2022 (the
“Second Amendment Date”) by and between Novartis Pharma AG a corporation with its principal place of business at Lichtstrasse 35, CH-4056 Basel, Switzerland and a successor in interest to
Novartis International Pharmaceutical Ltd. (“Novartis”), and Third Harmonic Bio, Inc. (hereinafter referred to as “NewCo”). Novartis and NewCo are each referred to individually as a “Party” and
together as the “Parties.” 
 WHEREAS, NewCo and Novartis are parties to that certain License Agreement effective as of
June 28, 2019 (the “Agreement”); 
 WHEREAS, Novartis transferred certain additional
Know-How pertaining to Licensed Compounds on December 21, 2021 (the “Delivery Date”), which Know-How constitutes Licensed
Know-How under the Agreement; 
 WHEREAS, Novartis and NewCo wish to amend Exhibit B of the
Agreement to reflect such additional Licensed Know-How; 
 NOW, THEREFORE, THE
PARTIES AGREE AS FOLLOWS: 
 1. Exhibit B of the Agreement is hereby replaced in its
entirety with the Exhibit B attached hereto and the content of such replacement Exhibit B will be considered to be Licensed Know-How. 

2. This Second Amendment is effective as of the Delivery Date and is and will be deemed to be an integral part of the Agreement. 

3. Any initially capitalized terms not otherwise defined herein shall have the meanings given in the Agreement. 

4. Except as expressly amended hereby, all terms of the Agreement shall remain unchanged and in full force and effect. 

5. This Second Amendment may be executed in multiple counterparts, each of which shall be deemed an original, but all of which together shall constitute one
and the same instrument. 
 IN WITNESS WHEREOF, the parties have duly executed this Second Amendment as of the Second Amendment Date. 

 

							
	NOVARTIS PHARMA AG	  	THIRD HARMONIC BIO, INC.
				
	By:	 	 /s/ Simone Pfirter
	  	By:	  	 /s/ Natalie Holles

	Name: Simone Pfirter	  	Name: Natalie Holles
	Title: Head NIBR General Legal Europe	  	Title: CEO

			
	By:	 	 /s/ Petra Grohmann-Moesching

	Name: Petra Grohmann-Moesching
	Title: Head Finance NIBR Europe

 Exhibit B

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00348-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00348-of-00352.parquet"}]]